var docs;if (!docs) docs =[]; docs["88"]={"8800":"<p><b>Title</b> Ledipasvir / Antacids</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Ledipasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Separate the administration of ledipasvir and antacids by 4 hours.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> Although no clinical studies have been conducted, prescribing information for the ledipasvir/sofosbuvir combination product states that ledipasvir solubility decreases with increasing gastric pH.<sup>1</sup> As such, drugs that increase gastric pH (eg, antacids) are expected to decrease serum concentrations of ledipasvir. The manufacturer recommends separating the administration of ledipasvir and antacids by 4 hours to minimize the risk of a clinically significant interaction.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Harvoni</i> (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8801":"<p><b>Title</b> Ledipasvir / Histamine H2 Receptor Antagonists</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Histamine H2 Receptor Antagonists may decrease the serum concentration of Ledipasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> H2 receptor antagonist doses less than or comparable to famotidine 40 mg twice daily can be administered simultaneously or 12 hours prior to ledipasvir. The effect of administering an H2 receptor antagonist at other time intervals in relation to ledipasvir administration is unknown and is not recommended by the manufacturer.</p>\n<div>\n <p><b>Histamine H2 Receptor Antagonists Interacting Members</b> Cimetidine, Famotidine, Lafutidine, Nizatidine, RaNITIdine</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ledipasvir/sofosbuvir prescribing information, administration of famotidine (40 mg single dose) with ledipasvir (90 mg single dose) or 12 hours prior to ledipasvir had no effect on the AUC of ledipasvir. When famotidine was administered simultaneously with ledipasvir, the maximum serum concentration (Cmax) decreased 20%. There was no change in ledipasvir Cmax when famotidine and ledipasvir were separated by 12 hours.<br><br>Prescribing information states that ledipasvir can be administered with H2-antagonists if given simultaneously or 12 hours prior to ledipasvir.<sup>1</sup> Since the solubility of ledipasvir decreases with increasing gastric pH, administration of an H2 receptor antagonist at other time intervals in relation to ledipasvir administration (ie, those that have not been evaluated in a clinical study) is not endorsed by the manufacturer.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Harvoni</i> (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8802":"<p><b>Title</b> Ledipasvir / Proton Pump Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the serum concentration of Ledipasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Proton pump inhibitor (PPI) doses comparable to omeprazole 20 mg or lower can be administered simultaneously with ledipasvir under fasted conditions. The use of higher doses of PPIs, administration of PPIs 2 hours prior to ledipasvir dosing, or use of PPIs in combination with food and ledipasvir may reduce the bioavailability of ledipasvir.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> In pharmacokinetic studies described in the ledipasvir/sofosbuvir prescribing information, administration of omeprazole (20 mg daily) 2 hours prior to ledipasvir (30 mg single dose) in 17 healthy volunteers resulted in a 42% and 48% decrease in ledipasvir AUC and maximum serum concentration (Cmax), respectively.<sup>1</sup> When omeprazole (20 mg daily) was given simultaneously with ledipasvir (90 mg single dose) in 16 healthy volunteers, there was no change in the AUC or Cmax of ledipasvir. Details surrounding the administration of food (or lack of) in these pharmacokinetic studies are not described.<sup>1</sup> In a retrospective analysis of 1,979 patients treated with ledipasvir/sofosbuvir, the rate of sustained virologic response (SVR) was similar between patients who received a proton pump inhibitor (PPI) compared with patients who did not take a PPI (97.1% vs 98.2%; p = 0.19).<sup>2</sup> In a subgroup analysis of patients who received twice daily PPI, SVR was lower compared with no PPI use (91.2% vs 98.2%; p = 0.042) However, after a propensity matched analysis and multivariable regression, PPI use (any dosing regimen) was not associated with a reduced SVR, except in a small subset of patients with cirrhosis where twice daily PPI was still associated with reduced SVR.<sup>2</sup> In an observational study of over 2,000 patients treated for hepatitis C with ledipasvir/sofosbuvir, PPI use was associated with a reduced chance of achieving SVR after multivariable adjustment (odds ratio [OR] 0.41; 95% CI 0.25 to 0.67).<sup>3</sup> Further statistical analysis (ie, pseudo-randomization) to balance baseline predictors of SVR among groups, still resulted in PPI use being associated with a reduced chance of achieving SVR (OR 0.57; 95% CI 0.25 to 0.67). <sup>3</sup><br><br>The solubility of ledipasvir decreases with increasing gastric pH and is the likely mechanism for this potential interaction. According to the manufacturer, proton pump inhibitor (PPI) doses that are comparable to or lower than omeprazole 20 mg can be administered simultaneously with ledipasvir under fasted conditions. There are no recommendations for the use of PPIs at higher doses, administration with food, or administration 2 hours prior to ledipasvir.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; February 2017.</p>\n<p>2. Tapper EB, Bacon BR, Curry MP, et al. Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study. <i>Hepatology</i>. 2016;64(6):1893-1899. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27533287\">[PubMed 27533287]</a></p>\n<p>3. Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. <i>Gastroenterology</i>. 2016;151(6):1131-1140.e5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27565882\">[PubMed 27565882]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8803":"<p><b>Title</b> Rosuvastatin / Ledipasvir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ledipasvir may increase the serum concentration of Rosuvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of ledipasvir and rosuvastatin.</p> \n<p><b>Discussion</b> Prescribing information for the ledipasvir/sofosbuvir combination product warns that coadministration with rosuvastatin may result in increased rosuvastatin concentrations and that concomitant use should be avoided.<sup>1</sup> No clinical studies have been conducted assessing this potential interaction.<br><br>Although not explicitly stated, the proposed mechanism for this potential interaction is likely inhibition of the breast cancer resistance protein by ledipasvir, a transporter at least partially responsible for rosuvastatin excretion.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Harvoni</i> (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. Zhang W, Yu BN, He YJ, et al. Role of BCRP 421C&gt;A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. <i>Clin Chim Acta</i>. 2006;373(1-2):99-103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16784736\">[PubMed 16784736]</a></p>\n<p>3. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. <i>Drug Metab Dispos</i>. 2008;36(10):2014-2023. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18617601\">[PubMed 18617601]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8804":"<p><b>Title</b> Simeprevir / Ledipasvir</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Simeprevir may increase the serum concentration of Ledipasvir. Ledipasvir may increase the serum concentration of Simeprevir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of ledipasvir and simeprevir.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ledipasvir/sofosbuvir prescribing information, coadministration of simeprevir (150 mg daily) with ledipasvir (30 mg daily) resulted in a 92% increase in ledipasvir AUC and an 81% increase in ledipasvir maximum serum concentration (Cmax) in 22 healthy volunteers.<sup>1</sup> The AUC and Cmax of simeprevir increased 169% and 161%, respectively. <br><br>In another study in 20 HCV-infected patients, the combination of ledipasvir (90 mg daily for 7 days) and simeprevir (150 mg daily for 14 days) also resulted in increased pharmacokinetic parameters for both drugs. Ledipasvir AUC and Cmax increased by 75% an 64% and simeprevir AUC and Cmax increased by 205% and 134%, respectively.<sup>2</sup><br><br>Due to the increases in exposure of both ledipasvir and simeprevir when these agents are used concomitantly, the prescribing information for ledipasvir/sofosbuvir and simeprevir recommends avoiding this combination.<sup>1,2</sup><br><br>The mechanism of this interaction has not been evaluated, but both drugs are substrates and inhibitors of P-glycoprotein, which may explain the increases in exposure of both agents when used concomitantly.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. Olysio (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8805":"<p><b>Title</b> Ledipasvir / OXcarbazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of Ledipasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of ledipasvir and oxcarbazepine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ledipasvir/sofosbuvir prescribing information, rifampin (600 mg daily) decreased the ledipasvir (90 mg single dose) AUC 59% and decreased the maximum serum concentration (Cmax) 35% in 31 healthy volunteers.<sup>1</sup><br><br>The prescribing information recommends avoiding concomitant use with agents that induce P-glycoprotein (P-gp), due to the potential for diminished ledipasvir exposure and effects.<sup>1</sup> Rifabutin, rifapentine, and oxcarbazepine are listed in the prescribing information as agents that potentially interact via this mechanism despite a lack of specific P-gp inducing properties of these agents in the published literature. However, all of these agents induce CYP-450 enzymes, are closely related to established P-gp inducers (eg, rifampin), and rifabutin and rifapentine induction of P-gp is supported by some in vitro data.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Harvoni</i> (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. <i>Antimicrob Agents Chemother</i>. 2013;57(12):6366-6369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24060875\">[PubMed 24060875]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8806":"<p><b>Title</b> Ledipasvir / Rifabutin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifabutin may decrease the serum concentration of Ledipasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of ledipasvir and rifabutin.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ledipasvir/sofosbuvir prescribing information, rifampin (600 mg daily) decreased the ledipasvir (90 mg single dose) AUC 59% and decreased the maximum serum concentration (Cmax) 35% in 31 healthy volunteers.<sup>1</sup><br><br>The prescribing information recommends avoiding concomitant use with agents that induce P-glycoprotein (P-gp), due to the potential for diminished ledipasvir exposure and effects.<sup>1</sup> Rifabutin, rifapentine, and oxcarbazepine are listed in the prescribing information as agents that potentially interact via this mechanism despite a lack of specific P-gp inducing properties of these agents in the published literature. However, all of these agents induce CYP-450 enzymes, are closely related to established P-gp inducers (eg, rifampin), and rifabutin and rifapentine induction of P-gp is supported by some in vitro data.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Harvoni</i> (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. <i>Antimicrob Agents Chemother</i>. 2013;57(12):6366-6369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24060875\">[PubMed 24060875]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8807":"<p><b>Title</b> Ledipasvir / Rifapentine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rifapentine may decrease the serum concentration of Ledipasvir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of ledipasvir and rifapentine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ledipasvir/sofosbuvir prescribing information, rifampin (600 mg daily) decreased the ledipasvir (90 mg single dose) AUC 59% and decreased the maximum serum concentration (Cmax) 35% in 31 healthy volunteers.<sup>1</sup><br><br>The prescribing information recommends avoiding concomitant use with agents that induce P-glycoprotein (P-gp), due to the potential for diminished ledipasvir exposure and effects.<sup>1</sup> Rifabutin, rifapentine, and oxcarbazepine are listed in the prescribing information as agents that potentially interact via this mechanism despite a lack of specific P-gp inducing properties of these agents in the published literature. However, all of these agents induce CYP-450 enzymes, are closely related to established P-gp inducers (eg, rifampin), and rifabutin and rifapentine induction of P-gp is supported by some in vitro data.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Harvoni</i> (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; October 2014.</p>\n<p>2. Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. <i>Antimicrob Agents Chemother</i>. 2013;57(12):6366-6369. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24060875\">[PubMed 24060875]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8809":"<p><b>Title</b> Tenofovir Disoproxil Fumarate / Ledipasvir</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b>: Concurrent use of ledipasvir/sofosbuvir together with tenofovir, when used as part of the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination, is not recommended. Consider alternatives to use of ledipasvir/sofosbuvir together with tenofovir disoproxil fumarate and a ritonavir- or cobicistat-boosted anti-HIV protease inhibitor when possible. If such a combination must be used, increase monitoring for tenofovir-associated toxicities. Increased monitoring for tenofovir-associated toxicities should also occur if ledipasvir/sofosbuvir is used together with tenofovir disoproxil fumarate combined with efavirenz and emtricitabine or when tenofovir dioproxil is combined with emtricitabine and rilpivirine. Ledipasvir/sofosbuvir is not expected to interact significantly with tenofovir individually.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ledipasvir may increase the serum concentration of Tenofovir Disoproxil Fumarate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of ledipasvir/sofosbuvir together with tenofovir, when used as part of the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination, is not recommended. Consider alternatives to use of ledipasvir/sofosbuvir together with tenofovir disoproxil fumarate and a ritonavir- or cobicistat-boosted anti-HIV protease inhibitor when possible. If such a combination must be used, increase monitoring for evidence of tenofovir-associated toxicities. Increased monitoring for tenofovir-associated adverse events should also occur if ledipasvir/sofosbuvir is used together with tenofovir disoproxil fumarate combined with efavirenz and emtricitabine or when tenofovir dioproxil is combined with emtricitabine and rilpivirine. Ledipasvir/sofosbuvir is not expected to interact significantly with tenofovir individually.</p> \n<p><b>Discussion</b> According to both the US and Canadian labeling for ledipasvir/sofosbuvir, concurrent use with various tenofovir disoproxil fumarate-containing antiviral regimens was associated with a 35% to 98% increase in tenofovir AUC, a 32% to 79% increase in tenofovir maximum serum concentration (Cmax), and 47% to 130% increase in tenofovir minimum serum concentration (Cmin).<sup>1,2</sup> The studied tenofovir-containing combinations include atazanavir/ritonavir, emtricitabine, and tenofovir disoproxil fumarate; darunavir/ritonavir, emtricitabine, and tenofovir disoproxil fumarate; efavirenz, emtricitabine, and tenofovir disoproxil fumarate; and emtricitabine, rilpivirine, and tenofovir disoproxil fumarate.<br><br>Tenofovir-containing antiviral regimens had variable effects on ledipasvir pharmacokinetic variables. The ledipasvir AUC was an average of 96% higher with concurrent atazanavir/ritonavir, emtricitabine, and tenofovir; 12% higher with concurrent darunavir/ritonavir, emtricitabine, and tenofovir; 8% higher with concurrent emtricitabine, rilpivirine, and tenofovir; but 34% lower with concurrent efavirenz, emtricitabine, and tenofovir.<sup>1,2</sup> <br><br>Labeling recommends increased monitoring for tenofovir-associated adverse events in patients receiving ledipasvir/sofosbuvir together with many tenofovir disoproxil fumarate-containing regimens.<sup>1,2</sup> The safety of increases in tenofovir concentrations when combined with additional drugs that also increase tenofovir concentrations, such as HIV-protease inhibitor/ritonavir regimens, or when tenofovir disoproxil fumarate is given as part of elvitegravir/cobicistat/emtricitabine regimen, has not been established, and avoidance of these specific combinations is recommended in the US ledipasvir/sofosbuvir prescribing information,<sup>1</sup> but such avoidance is not specifically included in the Canadian product monograph.<sup>2</sup><br><br>The mechanism by which ledipasvir/sofosbuvir increases tenofovir concentrations is unknown, but tenofovir disoproxil fumarate is a substrate for breast cancer resistance protein, an efflux transporter that ledipasvir inhibits.<sup>1,2,3</sup> Additionally, the possible contribution of sofosbuvir to this apparent interaction is uncertain. Sofosbuvir (without ledipasvir) was shown to increase tenofovir Cmax by an average of 25%, with no significance change in AUC or Cmin, when sofosbuvir was given together with a combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Harvoni (ledipasvir and sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; October 2014.</p>\n<p>2. Harvoni (ledipasvir and sofosbuvir) [product monograph]. Mississauga, ON: Gilead Sciences Canada, Inc.; October 2014.</p>\n<p>3. Viread (tenofovir disoproxil fumarate) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; October 2013.</p>\n<p>4. Sovaldi (sofosbuvir) [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8810":"<p><b>Title</b> Nintedanib / Anticoagulants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Carefully consider the potential increased risk for bleeding with use of this combination. Increase monitoring for signs and symptoms of potential bleeding if using nintedanib together with an anticoagulant, and adjust therapy as needed.</p>\n<div>\n <p><b>Anticoagulants Interacting Members</b> Acenocoumarol, Antithrombin, Apixaban, Argatroban, Bemiparin, Betrixaban, Bivalirudin, Dabigatran Etexilate, Dalteparin, Danaparoid, Desirudin, Edoxaban, Enoxaparin, Fondaparinux, Heparin, Nadroparin, Phenindione, Protein C Concentrate (Human), Rivaroxaban, Tinzaparin, Warfarin</p>\n</div> \n<p><b>Discussion</b> Specific data concerning the risk with use of this combination are not available, but the prescribing information for nintedanib cautions that concurrent use with an anticoagulant may increase the risk for bleeding.<sup>1</sup> Nintedanib use was associated with bleeding in clinical trials (10% vs. 7% with placebo), an effect largely attributed to its activity as an inhibitor of vascular endothelial growth factor (VEGF).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ofev</i> (nintedanib) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8811":"<p><b>Title</b> Nintedanib / Pirfenidone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pirfenidone may decrease the serum concentration of Nintedanib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> If this combination must be used, monitor patients closely for evidence of diminished response to nintedanib.</p> \n<p><b>Discussion</b> The nintedanib AUC and maximum serum concentration (Cmax) were reduced by an average of 32% and 41%, respectively, when combined with pirfenidone according to a study of patients with idiopathic pulmonary fibrosis that is mentioned in the nintedanib prescribing information.<sup>1</sup> The clinical significance of such a decrease is uncertain, though the prescribing information does recommend avoiding concurrent use with rifampin and other inducers of both P-glycoprotein and CYP3A4 based on data showing a 50% reduction in nintedanib AUC and a 40% reduction in nintedanib Cmax.<sup>1</sup><br><br>The specific mechanism for this apparent interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ofev</i> (nintedanib) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8814":"<p><b>Title</b> Methotrexate / Dexketoprofen</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dexketoprofen may increase the serum concentration of Methotrexate. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of dexketoprofen with methotrexate doses of 15 mg/week or more is inadvisable due to the potential for dexketoprofen to increase methotrexate hematologic toxicity. Use of dexketoprofen with lower methotrexate doses should only be performed with caution and increased monitoring. Monitor patients for hematologic toxicity by monitoring blood counts during the first several weeks of concurrent use. Patients with even mildly impaired renal function require more frequent monitoring.</p> \n<p><b>Discussion</b> According to the dexketoprofen summary of product characteristics, concurrent use of dexketoprofen with methotrexate doses of 15 mg/week or more is inadvisable due to the potential for dexketoprofen to increase methotrexate hematologic toxicity through impaired renal clearance of methotrexate.<sup>1,2,3</sup> Although the pharmacokinetics of methotrexate have not been specifically studied with dexketoprofen, other nonsteroidal anti-inflammatory agents (NSAIDs) have been studied in this context. Indomethacin and tolmetin have been reported to increase the AUC of methotrexate from 19% to 140% in pediatric patients.<sup>4</sup> Etodolac is reported to increase methotrexate half-life by 38% without any change in AUC,<sup>5</sup> and ibuprofen may decrease methotrexate clearance by 40% to 50%.<sup>6,7</sup> Some NSAIDs may decrease renal excretion of methotrexate by inhibiting renal transport proteins<sup>8,9,10</sup> and/or decreasing renal perfusion. In contrast, other reports conclude that ibuprofen, indomethacin, and several other NSAIDs do not significantly affect methotrexate pharmacokinetics.<sup>11,12,13,14,15,16,17,18</sup><br><br>Regardless of pharmacokinetic changes, several other NSAIDs not independently associated with hematologic toxicities have been associated with the development of methotrexate toxicity (neutropenia, thrombocytopenia, kidney failure) as soon as a day after NSAID initiation in methotrexate-stable patients.<sup>19,20,21,22,23,24</sup> In addition, some NSAIDs may have additive toxicities with methotrexate (e.g., indomethacin - renal toxicity).</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Keral</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>2. <i>Enantyum</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>3. <i>Ketesse</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International Operation Luxembourg S.A.; January 2013.</p>\n<p>4. Dupuis LL, Koren G, Shore A, Silverman ED, Laxer RM. Methotrexate-nonsteroidal anti-inflammatory drug interaction in children with arthritis. <i>J Rheumatol</i>. 1990;17:1469-1473. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2273487\">[PubMed 2273487]</a>]</p>\n<p>5. Anaya JM, Fabre D, Bressolle F, et al. Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. <i>J Rheumatol</i>. 1994;21:203-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8182625\">[PubMed 8182625]</a></p>\n<p>6. Tracy TS, Jones DR, Hall SK, Brater DC, Bradley JD, Krohn K. The effect of NSAIDs on methotrexate disposition in patients with rheumatoid arthritis. <i>Clin Pharmacol Ther</i>. 1990;47:138 [Abstract 54].</p>\n<p>7. Tracy TS, Krohn K, Jones DR ,Bradley JD, Hall SD, Brater DC. The effects of salicylate, ibuprofen, and naproxen on the disposition of metotrexate in patients with rheumatoid arthritis. <i>Eur J Clin Pharmacol</i>. 1992;42:121-125. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1618240\">[PubMed 1618240]</a></p>\n<p>8. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. <i>J Pharmacol Exp Ther</i>. 2007;320(1):229-235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17005917\">[PubMed 17005917]</a></p>\n<p>9. Nozaki Y, Kusuhara H, Endou H, Sugiyama Y. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. <i>J Pharmacol Exp Ther</i>. 2004;309(1):226-234. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14722319\">[PubMed 14722319]</a></p>\n<p>10. Takeda M, Khamdang S, Narikawa S. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. <i>J Pharmacol Exp Ther</i>. 2002;302(2):666-671. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12130730\">[PubMed 12130730]</a></p>\n<p>11. Karin A, Tolbert D, Piergies A, et al. Celecoxib, a specific COX-2 inhibitor, lacks significant drug-drug interactions with methotrexate or warfarin. <i>Arthritis Rheum</i>. 1998;41(Suppl 9):S315. [Abstract]</p>\n<p>12. Iqbal MP, Baig JA, Ali AA,Niazi SK, Mehboobali N, Hussain MA. The effects of nonsteroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. <i>Biopharm Drug Dispos</i>. 1998;19:163-167. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9569999\">[PubMed 9569999]</a></p>\n<p>13. Skeith KJ, Russell AS, Jamali F, Coates J, Friedman H. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. <i>J Rheumatol</i>. 1990;17:1008-1010. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2213774\">[PubMed 2213774]</a></p>\n<p>14. Tracy TS, Worster T, Bradley JD, Greene PK, Brater DC. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam, and flurbiprofen in patients with rheumatoid arthritis. <i>Br J Clin Pharmac</i>. 1994;37:453-456. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8054251\">[PubMed 8054251]</a></p>\n<p>15. Christophidis N, Dawson TM, Angelis P, et al. A double-blind, randomized, placebo controlled pharmacokinetic and clinical study of the interaction of ketoprofen and naproxen with methotrexate in rheumatoid arthritis. <i>Arthritis Rheum</i>. 1994; 37(Suppl 9):S252. [Abstract] </p>\n<p>16. Stewart CF, Fleming RA, Arkin CR, Evans WE. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. <i>Clin Pharmacol Ther</i>. 1990;47:540-546. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2328562\">[PubMed 2328562]</a></p>\n<p>17. Combe B, Edno L, Lafforgue P, et al. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. <i>Br J Rheumatol</i>. 1995;34:421-428. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7788170\">[PubMed 7788170]</a></p>\n<p>18. Huebner G, Sander D, Degner FL, Turck D, Rau R. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. <i>J Rheumatol</i>. 1997;24:845-851. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9150070\">[PubMed 9150070]</a></p>\n<p>19. Frenia ML, Long KS. Methotrexate and nonsteroidal anti-inflammatory drug interaction. <i>Ann Pharmacother</i>. 1992;26:234-237. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1554938\">[PubMed 1554938]</a></p>\n<p>20. Cassano W. Serious methotrexate toxicity caused by interaction with ibuprofen. <i>Am J Ped Hematol/Oncol</i>. 1989;11:481-482. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2618985\">[PubMed 2618985]</a></p>\n<p>21. Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. <i>Lancet</i>. 1986;1(8475):256-258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2868265\">[PubMed 2868265]</a></p>\n<p>22. Singh RR, Malaviya AN, Pandey JN, Guleria JS. Fatal interaction between methotrexate and naproxen. <i>Lancet</i>. 1986;1(8494):1390. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2872507\">[PubMed 2872507]</a></p>\n<p>23. Adams JD, Hunter G. Drug interaction in psoriasis. <i>Aust J Dermatol</i>. 1976;17:39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1022213\">[PubMed 1022213]</a></p>\n<p>24. Mayall B, Poggi G, Parkin JD. Neutropenia due to low-dose methotrexate therapy for psoriasis and rheumatoid arthritis may be fatal. <i>Med J Aust</i>. 1991;155:480-484. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1921820\">[PubMed 1921820]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8815":"<p><b>Title</b> Dexketoprofen / Salicylates</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Use of dexketoprofen with very high salicylate doses (3 g/day or more) is not advisable. A potential interaction remains with lower doses of salicylates, but that interaction can be managed with increased patient monitoring and/or changes in the timing of drug administration.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Salicylates may enhance the adverse/toxic effect of Dexketoprofen. Dexketoprofen may diminish the therapeutic effect of Salicylates. Salicylates may decrease the serum concentration of Dexketoprofen. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The use of high-dose salicylates (3 g/day or more) together with dexketoprofen is inadvisable due to a possible increased risk for gastrointestinal ulceration and bleeding according to the dexketoprofen summary of product characteristics. With concurrent use of lower-dose salicylates monitor patients closely for evidence of bleeding. Additionally, nonselective NSAIDs, like dexketoprofen, may reduce the cardioprotective effects of aspirin; thus, it seems prudent to avoid regular, frequent use of such NSAIDs in patients receiving aspirin for its cardioprotective effects. Alternative analgesics (e.g., acetaminophen) may be a safer choice. Occasional NSAID use is unlikely to cause clinically significant problems. Patients may require counseling about the optimal timing of dexketoprofen and aspirin dosing to minimize any potential interaction; dexketoprofen should be administered 30-120 minutes after, or at least 8 hours before, aspirin.</p>\n<div>\n <p><b>Salicylates Interacting Members</b> Aminosalicylic Acid, Aspirin, Bismuth Subsalicylate, Choline Salicylate, Magnesium Salicylate, Salsalate, Sodium Salicylate, Triflusal<br><b>Exception</b> Choline Magnesium Trisalicylate</p>\n</div> \n<p><b>Discussion</b> According to the dexketoprofen summary of product characteristics, the use of high-dose salicylates (3 g/day or more) together with dexketoprofen is inadvisable due to a possible increased risk for gastrointestinal ulceration and bleeding.<sup>1,2,3</sup><br><br>The combination of a salicylate and a nonsteroidal anti-inflammatory drug (NSAID) may increase the risk of gastrointestinal bleeding given the potential for both agents to inhibit gastrointestinal protective factors mediated by prostaglandins produced via the action of cyclooxygenase (COX). Further, aspirin has been noted to decrease serum concentrations of a variety of NSAIDs, sometimes by more than 50% (e.g., flurbiprofen).<sup>4,5,6,7,8,9,10,11,12,13,14,15</sup> The interactions appear to be of minimal clinical significance. The mechanism(s) for these interactions are likely related to the potential for aspirin to displace the NSAID from plasma protein binding sites, thus increasing the potential for its elimination. The clinical effect of this interaction may be muted by the combined effect of a relative increase in free (unbound) NSAID, and the anti-inflammatory activity of aspirin.<br><br>Finally, some data suggest that the NSAIDs ibuprofen and naproxen may limit the cardioprotective antiplatelet effect of aspirin.<sup>16,17,18</sup> Other data suggest that the NSAID, alone, may provide cardioprotection, but does not enhance the protection provided by aspirin if coadministered.<sup>19</sup> Analysis of an electronic prescription database of patients with cardiovascular disease who were taking aspirin revealed a higher frequency of cardiovascular mortality in patients also taking ibuprofen.<sup>20</sup> A cohort study of 4,975 cases of acute myocardial infarction failed to demonstrate any clinically significant pharmacodynamic interaction between aspirin and NSAIDs on the risk of acute myocardial infarction.<sup>21</sup> Both agents are COX inhibitors. COX-1 catalyzes a process that eventually produces thromboxane A<sub>2</sub>, a substance that catalyzes both platelet activation and local vasoconstriction. Aspirin is an irreversible COX inhibitor, whereas ibuprofen and other NSAIDs are reversible inhibitors. It is surmised that ibuprofen may exhibit greater affinity than aspirin for the active site on the enzyme, or, if dosed regularly (or prior to aspirin) it would gain first access to the active site. In either case, aspirin inhibition of COX (irreversible) would be limited in favor of ibuprofen inhibition (reversible), thus affording reduced overall COX inhibition. Agents with greater preference for the COX-2 receptors (those associated with inflammation) would appear to be of less risk.<sup>22</sup> A definitive understanding of this purported interaction is lacking. Caution is advised.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Keral</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>2. <i>Enantyum</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International O.L.S.A.; February 2012.</p>\n<p>3. <i>Ketesse</i> (dexketoprofen) [summary of product characteristics]. Luxembourg: Menarini International Operation Luxembourg S.A.; January 2013.</p>\n<p>4. Rubin A, Rodda BE, Warrick P, Gruber CM Jr, Ridolfo AS. Interactions of aspirin with nonsteroidal antiinflammatory drugs in man. <i>Arthritis Rheum</i>. 1973;16(5):635-645. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4582611\">[PubMed 4582611]</a></p>\n<p>5. Kaiser DG, Brooks CD, Lomen PL. Pharmacokinetics of flurbiprofen. <i>Am J Med</i>. 1986;80(3A):10-15. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3963013\">[PubMed 3963013]</a></p>\n<p>6. Brooks PM, Khong TK. Flurbiprofen-aspirin interaction: a double-blind crossover study. <i>Curr Med Res Opin</i>. 1977;5(1):53-57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=71972\">[PubMed 71972]</a></p>\n<p>7. Grennan DM, Ferry DG, Ashworth ME, Kenny RE, Mackinnon M. The aspirin-ibuprofen interaction in rheumatoid arthritis. <i>Br J Clin Pharmacol</i>. 1979;8(5):497-503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=389264\">[PubMed 389264]</a></p>\n<p>8. Jeremy R, Towson J. Interaction between aspirin and indomethacin in the treatment of rheumatoid arthritis. <i>Med J Aust</i>. 1970;2(3):127-129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5455762\">[PubMed 5455762]</a></p>\n<p>9. Kwan KC, Breault GO, Davis RL, et al. Effects of concomitant aspirin administration on the pharmacokinetics of indomethacin in man. <i>J Pharmacokinet Biopharm</i>. 1978;6(6):451-476. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=731412\">[PubMed 731412]</a></p>\n<p>10. Torgyan S, Wagner L, Neumann T, Pakuts B, Csanyi M. A comparative study with indomethacin and combined indomethacin sodium-salicylate in rheumatoid arthritis. <i>Int J Clin Pharmacol Biopharm</i>. 1979;17(11):439-441. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=389838\">[PubMed 389838]</a></p>\n<p>11. Alvan G, Ekstrand R. Clinical effects of indomethacin and additive clinical effect of indomethacin during salicylate maintenance therapy. <i>Scand J Rheumatol Suppl</i>. 1981;39:29-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6946553\">[PubMed 6946553]</a></p>\n<p>12. Williams RL, Upton RA, Buskin JN, Jones RM. Ketoprofen-aspirin interactions. <i>Clin Pharmacol Ther</i>. 1981;30(2):226-231. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7249506\">[PubMed 7249506]</a></p>\n<p>13. Segre EJ, Chaplin M, Forchielli E, Runkel R, Sevelius H. Naproxen-aspirin interactions in man. <i>Clin Pharmacol Ther</i>. 1974;15(4):374-379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4821440\">[PubMed 4821440]</a></p>\n<p>14. Hobbs DC, Twomey TM. Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. <i>J Clin Pharmacol</i>. 1979;19(5-6):270-281. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=89124\">[PubMed 89124]</a></p>\n<p>15. Cressman WA, Wortham GF, Plostnieks J. Absorption and excretion of tolemetin in man. <i>Clin Pharmacol Ther</i>. 1976;19(2):224-233. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1261159\">[PubMed 1261159]</a></p>\n<p>16. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. <i>Lancet</i>. 2003;361(9357):573-574. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12598144\">[PubMed 12598144]</a></p>\n<p>17. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. <i>N Engl J Med</i>. 2001;345(25):1809-1817. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11752357\">[PubMed 11752357]</a></p>\n<p>18. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. <i>J Am Coll Cardiol</i>. 2005;45(8):1295-1301. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15837265\">[PubMed 15837265]</a></p>\n<p>19. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. <i>J Am Coll Cardiol</i>. 2004;43(6):985-990. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15028354\">[PubMed 15028354]</a></p>\n<p>20. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. <i>Lancet</i>. 2003;361(9357):573-574. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12598144\">[PubMed 12598144]</a></p>\n<p>21. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. <i>Circulation</i>. 2004;109(24):3000-3006. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15197149\">[PubMed 15197149]</a></p>\n<p>22. FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. <i>Lancet</i>. 2003;361(9357):542-544. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12598136\">[PubMed 12598136]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8816":"<p><b>Title</b> Tofacitinib / Methotrexate</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Tofacitinib use should be avoided in combination with potent immunosuppressive methotrexate-containing regimens.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Methotrexate may enhance the immunosuppressive effect of Tofacitinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Tofacitinib should not be used in combination with potent immunosuppressants. Of note, concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.</p> \n<p><b>Discussion</b> Tofacitinib US prescribing information states that it should not be used with potent immunosuppressant, such as azathioprine, cyclosporine, or tacrolimus.<sup>1</sup> Specific data concerning the use of such combinations are not available, but given the immunosuppressive actions of tofacitinib, additive immunosuppressant actions are possible with such combinations.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Xeljanz</i> (tofacitinib) [prescribing information]. New York, NY: Pfizer Inc; November 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8823":"<p><b>Title</b> HMG-CoA Reductase Inhibitors (Statins) / Acipimox</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acipimox may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for muscle toxicities (myalgia, myositis, rhabdomyolysis) if acipimox is combined with an HMG-CoA reductase inhibitor.</p>\n<div>\n <p><b>HMG-CoA Reductase Inhibitors (Statins) Interacting Members</b> AtorvaSTATin, Fluvastatin, Lovastatin, Pitavastatin, Pravastatin, Red Yeast Rice, Rosuvastatin, Simvastatin</p>\n</div> \n<p><b>Discussion</b> No clinical studies have been conducted with acipimox and HMG-CoA reductase inhibitors (statins). However, due to the structural similarity between acipimox and niacin, product labeling for acipimox warns that increases in muscle toxicities (myalgia, myositis, rhabdomyolysis) may occur if acipimox is combined with statins.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Olbetam</i> (acipimox) [summary of product characteristics]. Sandwich, Kent, United Kingdom: Pfizer Limited; March 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8824":"<p><b>Title</b> Fibric Acid Derivatives / Acipimox</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Acipimox may enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for muscle toxicities (myalgia, myositis, rhabdomyolysis) if acipimox is combined with a fibric acid derivative.</p>\n<div>\n <p><b>Fibric Acid Derivatives Interacting Members</b> Bezafibrate, Ciprofibrate, Fenofibrate and Derivatives, Gemfibrozil</p>\n</div> \n<p><b>Discussion</b> No clinical studies have been conducted with acipimox and fibric acid derivatives. However, due to the structural similarity between acipimox and niacin, product labeling for acipimox warns that increases in muscle toxicities (myalgia, myositis, rhabdomyolysis) may occur if acipimox is combined with a fibric acid derivative.<sup>1</sup> Although there are no reported data of an interaction between fibric acid derivatives and niacin or acipimox, all have been associated with the development of muscle toxicities.<sup>1,2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Olbetam</i> (acipimox) [summary of product characteristics]. Sandwich, Kent, United Kingdom: Pfizer Limited; March 2014.</p>\n<p>2. <i>Niaspan</i> (niacin extended-release) [prescribing information]. North Chicago, IL: Abbott Laboratories; February 2013.</p>\n<p>3. <i>Lopid</i> (gemfibrozil) [prescribing information]. New York, NY: Pfizer Inc; October 2013.</p>\n<p>4. <i>Tricor</i> (fenofibrate) [prescribing information]. North Chicago, IL: Abbott Laboratories; February 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8825":"<p><b>Title</b> CYP1A2 Substrates (High risk with Inducers) / Teriflunomide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Teriflunomide may decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for reduced systemic concentrations and effects of CYP1A2 substrates during concomitant teriflunomide use.</p>\n<div>\n <p><b>CYP1A2 Substrates (High risk with Inducers) Interacting Members</b> Acebrophylline, Acenocoumarol, Aminophylline, Asenapine, ClomiPRAMINE, Dacarbazine, DULoxetine, Estradiol (Systemic), Estradiol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estropipate, Flutamide, FluvoxaMINE, Lidocaine (Systemic), Melatonin, Mexiletine, Mirtazapine, OLANZapine, Pimozide, Pirfenidone, Propranolol, Ramosetron, Rasagiline, ROPINIRole, Stiripentol, Tasimelteon, Theophylline, Thiothixene, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in teriflunomide US prescribing information, repeated doses of teriflunomide reduced the caffeine maximum concentration and AUC by 18% and 55%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is teriflunomide induction of CYP1A2 mediated caffeine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aubagio</i> (teriflunomide) [prescribing information]. Cambridge, MA: Genzyme Corporation; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8826":"<p><b>Title</b> OAT3 Substrates / Teriflunomide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Teriflunomide may increase the serum concentration of OAT3 Substrates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased systemic concentrations and effects of OAT3 substrates during concomitant teriflunomide use.</p>\n<div>\n <p><b>OAT3 Substrates Interacting Members</b> Adefovir, Anagliptin, Avibactam, Cefaclor*, Cimetidine, Ciprofloxacin (Systemic), Eluxadoline, Empagliflozin, Furosemide, Ketoprofen, Methotrexate, Mycophenolate, PEMEtrexed, Penicillin G (Parenteral/Aqueous), Penicillin G Benzathine, Penicillin G Procaine, Penicillin V Benzathine, Penicillin V Potassium, Zidovudine</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in teriflunomide US prescribing information, repeated doses of teriflunomide increased the maximum concentration and AUC of cefaclor by 1.4 and 1.5 fold, respectively<sup>1</sup> The suspected primary mechanism of this interaction is teriflunomide inhibition of OAT3 mediated cefaclor excretion.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aubagio</i> (teriflunomide) [prescribing information]. Cambridge, MA: Genzyme Corporation; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8827":"<p><b>Title</b> Rosuvastatin / Teriflunomide</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Teriflunomide may increase the serum concentration of Rosuvastatin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit the maximum adult rosuvastatin dose to 10 mg/day in patients receiving teriflunomide, and monitor for evidence of rosuvastatin toxicity (eg, muscle toxicity, elevated transaminase concentrations).</p> \n<p><b>Discussion</b> In a clinical study summarized in teriflunomide US prescribing information, repeated doses of teriflunomide increased the maximum concentration and AUC of rosuvastatin by 2.7 and 2.5 fold, respectively.<sup>1</sup> The proposed primary mechanism of this interaction is teriflunomide inhibition of BCRP, SLCO1B1, and SLCO1B3 mediated rosuvastatin transport.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aubagio</i> (teriflunomide) [prescribing information]. Cambridge, MA: Genzyme Corporation; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8828":"<p><b>Title</b> BCRP/ABCG2 Substrates / Teriflunomide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Teriflunomide may increase the serum concentration of BCRP/ABCG2 Substrates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased systemic concentrations and/or effects of BCRP substrates during concomitant teriflunomide use.</p>\n<div>\n <p><b>BCRP/ABCG2 Substrates Interacting Members</b> Glecaprevir and Pibrentasvir, PAZOPanib, Rosuvastatin, SulfaSALAzine, Topotecan</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in teriflunomide US prescribing information, repeated doses of teriflunomide increased the maximum concentration and AUC of rosuvastatin by 2.7 and 2.5 fold, respectively.<sup>1</sup> The proposed primary mechanism of this interaction is teriflunomide inhibition of BCRP, SLCO1B1, and SLCO1B3 mediated rosuvastatin transport.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aubagio</i> (teriflunomide) [prescribing information]. Cambridge, MA: Genzyme Corporation; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8829":"<p><b>Title</b> OATP1B1/SLCO1B1 Substrates / Teriflunomide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Teriflunomide may increase the serum concentration of OATP1B1/SLCO1B1 Substrates. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased systemic concentrations and/or effects of SLCO1B1 substrates during concomitant teriflunomide use.</p>\n<div>\n <p><b>OATP1B1/SLCO1B1 Substrates Interacting Members</b> Asunaprevir, AtorvaSTATin, Bosentan, Eluxadoline, Ezetimibe, Fexofenadine, Fimasartan, Fluvastatin, Glecaprevir and Pibrentasvir, Grazoprevir, Irinotecan (Conventional), Irinotecan (Liposomal), Letermovir, Methotrexate, Nateglinide, Olmesartan, Pitavastatin, Pravastatin, Repaglinide, RifAMPin, Rosuvastatin*, Simeprevir, Simvastatin, Torsemide, Valsartan, Voxilaprevir</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in teriflunomide US prescribing information, repeated doses of teriflunomide increased the maximum concentration and AUC of rosuvastatin by 2.7 and 2.5 fold, respectively.<sup>1</sup> The proposed primary mechanism of this interaction is teriflunomide inhibition of BCRP, SLCO1B1, and SLCO1B3 mediated rosuvastatin transport.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aubagio</i> (teriflunomide) [prescribing information]. Cambridge, MA: Genzyme Corporation; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8831":"<p><b>Title</b> Dronedarone / Tacrolimus (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Tacrolimus (Systemic) may enhance the QTc-prolonging effect of Dronedarone. Dronedarone may increase the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased serum tacrolimus concentrations, tacrolimus toxicity, and QTc interval prolongation if combined with dronedarone. Tacrolimus dose adjustments may be needed.</p> \n<p><b>Discussion</b> One case report describes a 63-year-old man who was stabilized on dronedarone at the time of kidney transplantation.<sup>1</sup> After induction with basiliximab, extended release tacrolimus 12 mg daily (0.15 mg/kg/day) was started on post-operative day 1 (in combination with mycophenolate and corticosteroids). On post-operative day 3, tacrolimus concentrations had risen to 22.2 ng/mL, further increasing to greater than 30 ng/mL despite decreasing doses of tacrolimus. The patient experienced tremor, hyperkalemia, and nausea, but no change in QTc interval. Three weeks later his tacrolimus levels stabilized at 13.3 ng/mL with a 50% tacrolimus dose reduction to 6 mg daily (0.075 mg/kg/day).<sup>1</sup><br><br>The mechanism of this potential interaction has not been specifically evaluated, but CYP3A4 and P-glycoprotein (P-gp) inhibition by dronedarone is likely responsible for increased tacrolimus (a CYP3A4 and P-gp substrate) exposure.<sup>2,3</sup> Additionally, both dronedarone and tacrolimus have been shown to increase the QTc interval and their combination should be used with caution.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Marin-Casino M, Perez-Saez MJ, Crespo M, Echeverria D, Mir M, Pascual J. Significant tacrolimus and dronedarone interaction in a kidney transplant recipient. <i>Transplantation</i>. 2014;98(4):e33-e34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25243519\">[PubMed 25243519]</a></p>\n<p>2. <i>Multaq</i> (dronedarone) [prescribing information]. Bridgewater, NJ: Sanofii-Aventis; March 2014.</p>\n<p>3. <i>Prograf</i> (tacrolimus) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; August 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8832":"<p><b>Title</b> Acetaminophen / Lixisenatide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Lixisenatide may decrease the serum concentration of Acetaminophen. More specifically, Lixisenatide may decrease the rate of Acetaminophen absorption, with questionable impact on the extent of absorption. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action is required. Acetaminophen onset of action may be delayed somewhat when administered 1 to 4 hours after lixisenatide.</p> \n<p><b>Discussion</b> In clinical studies summarized in the lixisenatide prescribing information, administration of acetaminophen (1 g single oral dose) 1 hour before or 1 or 4 hours after lixisenatide (10 mcg) was not associated with any change in acetaminophen half-life or AUC.<sup>1</sup> However, administration of acetaminophen 1 or 4 hours after lixisenatide was associated with delayed absorption (2 and 1.75 hours, respectively) and an approximate 30% decrease in acetaminophen maximum concentration.<sup>1</sup> The suspected primary mechanism of this interaction is delayed acetaminophen absorption due to lixisenatide-associated reductions in gastric emptying rate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Adlyxin (lixisenatide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8833":"<p><b>Title</b> Vitamin K Antagonists / Lixisenatide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Lixisenatide may decrease the serum concentration of Vitamin K Antagonists. More specifically, Lixisenatide may decrease the rate of Vitamin K Antagonist absorption, with questionable impact on the extent of absorption. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in the lixisenatide prescribing information, lixisenatide (20 mcg daily) had no impact on warfarin (25 mg single dose) AUC or INR, but decreased the warfarin maximum concentration by 19% and delayed the time to reach this maximum concentration by 7 hours.<sup>1</sup> The suspected primary mechanism of this interaction is delayed warfarin absorption due to lixisenatide-associated reductions in gastric emptying rate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Adlyxin (lixisenatide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8839":"<p><b>Title</b> Atazanavir / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Atazanavir. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid coadministration of St. John's wort and atazanavir. This combination is listed as contraindicated in atazanavir US product labeling.</p> \n<p><b>Discussion</b> According to atazanavir US prescribing information, the concomitant use of St. John's wort and atazanavir should be avoided due to the potential for decreased atazanavir exposure, loss of therapeutic effect, and development of resistance.<sup>1</sup> The primary predicted mechanism of this interaction is St. John's wort induction of CYP3A mediated atazanavir metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Reyataz</i> (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; June 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8840":"<p><b>Title</b> Sirolimus / Aprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Aprepitant may increase the serum concentration of Sirolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor sirolimus concentrations and effects closely when used with aprepitant/fosaprepitant. Sirolimus dose reductions may be necessary.</p> \n<p><b>Discussion</b> Sirolimus concentrations measured 1 to 3 days after a sirolimus loading dose (12 mg for 1 dose, then 4 mg/day) were approximately 2.2-fold higher among patients that had received aprepitant (125 mg for 1 dose, then 80 mg/day on days 2 and 3) than among those who did not in a retrospective analysis of 85 consecutive patients receiving tacrolimus/sirolimus-based prophylaxis of graft-versus-host disease (n=14 aprepitant recipients and 71 control patients).<sup>1</sup> Due to the higher initial sirolimus concentrations, the clinicians often substantially reduced sirolimus doses, resulting in subtherapeutic sirolimus concentrations in 6 patients. Though these observations suggest that this apparent interaction is likely of high clinical significance, the case series nature of these data and the lack of any better-controlled study make any more definitive determination about either the magnitude or clinical impact of this interaction difficult.<br><br>The likely mechanism of this interaction is aprepitant inhibition of the CYP3A-mediated metabolism of sirolimus. Aprepitant is characterized as a weak-to-moderate inhibitor of CYP3A4 (depending on dose and duration).<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Shayani S, Palmer JM, Stiller T, et al. Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. <i>Bone Marrow Transplant</i>. 2012;47(2):291-293. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383680\">[PubMed 21383680]</a></p>\n<p>2. <i>Emend</i> (aprepitant/fosaprepitant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; March 2013.</p>\n<p>3. Majumdar AK, Yan KX, Selverian DV, et al. Effect of aprepitant on the pharmacokinetics of intravenous midazolam. <i>J Clin Pharmacol</i>. 2007;47(6):744-750. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17463213\">[PubMed 17463213]</a></p>\n<p>4. Majumdar AK, McCrea JB, Panebianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. <i>Clin Pharmacol Ther</i>. 2003;74(2):150-156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12891225\">[PubMed 12891225]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8841":"<p><b>Title</b> Sirolimus / Fosaprepitant</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fosaprepitant may increase the serum concentration of Sirolimus. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor sirolimus concentrations and effects closely when used with aprepitant/fosaprepitant. Sirolimus dose reductions may be necessary.</p> \n<p><b>Discussion</b> Sirolimus concentrations measured 1 to 3 days after a sirolimus loading dose (12 mg for 1 dose, then 4 mg/day) were approximately 2.2-fold higher among patients that had received aprepitant (125 mg for 1 dose, then 80 mg/day on days 2 and 3) than among those who did not in a retrospective analysis of 85 consecutive patients receiving tacrolimus/sirolimus-based prophylaxis of graft-versus-host disease (n=14 aprepitant recipients and 71 control patients).<sup>1</sup> Due to the higher initial sirolimus concentrations, the clinicians often substantially reduced sirolimus doses, resulting in subtherapeutic sirolimus concentrations in 6 patients. Though these observations suggest that this apparent interaction is likely of high clinical significance, the case series nature of these data and the lack of any better-controlled study make any more definitive determination about either the magnitude or clinical impact of this interaction difficult.<br><br>The likely mechanism of this interaction is aprepitant/fosaprepitant inhibition of the CYP3A-mediated metabolism of sirolimus. Aprepitant and fosaprepitant are characterized as a weak-to-moderate inhibitors of CYP3A4 (depending on dose and duration).<sup>2,3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Shayani S, Palmer JM, Stiller T, et al. Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. <i>Bone Marrow Transplant</i>. 2012;47(2):291-293. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21383680\">[PubMed 21383680]</a></p>\n<p>2. <i>Emend</i> (aprepitant/fosaprepitant) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; March 2013.</p>\n<p>3. Majumdar AK, Yan KX, Selverian DV, et al. Effect of aprepitant on the pharmacokinetics of intravenous midazolam. <i>J Clin Pharmacol</i>. 2007;47(6):744-750. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17463213\">[PubMed 17463213]</a></p>\n<p>4. Majumdar AK, McCrea JB, Panebianco DL, et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. <i>Clin Pharmacol Ther</i>. 2003;74(2):150-156. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12891225\">[PubMed 12891225]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8842":"<p><b>Title</b> Rosuvastatin / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Rosuvastatin. <b>Severity</b> Minor <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> The rosuvastatin AUC and maximum serum concentration were an average of 38% and 89% higher, respectively, following concurrent administration of elvitegravir and cobicistat in a study of healthy volunteers (n=12) who received a single doses of rosuvastatin (10 mg) with or without concurrent elvitegravir/cobicistat (10-day treatment).<sup>1</sup> The clinical significance of these changes is uncertain but likely to be low.<br><br>The mechanism for this interaction is most likely elvitegravir- and/or cobicistat-mediated inhibition of the OATP-mediated transport of rosuvastatin. An in vitro study found that both elvitegravir and cobicistat were likely capable of inhibiting OATP at clinically relevant concentrations.<sup>1</sup> Inhibition of rosuvastatin transport via BCRP (ABCG2) may also contribute to this interaction, though both elvitegravir and cobicistat were far less potent inhibitors of this transporter in viro.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Custodio JM, Wang H, Hao J, et al. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin. <i>J Clin Pharmacol</i>. 2014;54(6):649-656. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24375014\">[PubMed 24375014]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8843":"<p><b>Title</b> Zopiclone / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The initial starting adult dose of zopiclone should not exceed 3.75 mg if combined with a strong CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity (eg, drowsiness, confusion, lethargy, ataxia, respiratory depression) if these agents are combined. If this combination is tolerated, the zopiclone dose may be increased to a maximum of 5 mg with close monitoring.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In one pharmacokinetic study, the zopiclone (7.5 mg single dose) AUC and maximum serum concentration (Cmax) increased 73% and 29%, respectively, when given after a 4-day course of the strong CYP3A4 inhibitor itraconazole (200 mg daily) in 10 healthy volunteers.<sup>1</sup> No changes in pharmacodynamic responses were seen between groups.<sup>1</sup> In another study of 10 healthy volunteers, the moderate CYP3A4 inhibitor erythromycin (500 mg three times daily for 6 days) increased the AUC and Cmax of zopiclone (7.5 mg single dose) by 80% and 40%, respectively.<sup>2</sup> A case report also describes an 86-year-old female who experienced elevated plasma levels of zopiclone along with excessive drowsiness while taking nefazodone (a strong CYP3A4 inhibitor) that resolved after nefazodone was discontinued.<sup>3</sup><br><br>Product labeling for zopiclone warns that plasma levels of zopiclone may increase if combined with CYP3A4 inhibitors since CYP3A4 is responsible for the majority of zopiclone metabolism.<sup>4,5</sup> As such, the recommended starting dose of zopiclone is 3.75 mg if used concomitantly with a strong CYP3A4 inhibitor.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Jalava KM, Olkkola KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. <i>Eur J Clin Pharmacol</i>. 1996;51(3-4):331-334. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9010708\">[PubMed 9010708]</a></p>\n<p>2. Aranko K, Luurila H, Backman JT, Neuvonen PJ, Olkkola KT. The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. <i>Br J Clin Pharmacol</i>. 1994;38(4):363-367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7833227\">[PubMed 7833227]</a></p>\n<p>3. Alderman CP, Gebauer MG, Gilbert AL, Condon JT. Possible interaction of zopiclone and nefazodone. <i>Ann Pharmacother</i>. 2001;35(11):1378-1380. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11724087\">[PubMed 11724087]</a></p>\n<p>4. <i>Imovane</i> (zopiclone) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; October 2014.</p>\n<p>5. Becquemont L, Mouaijah S, Escaffre O, Beaune P, Funck-Brentano C, Jaillon P. Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. <i>Drug Metab Dispos</i>. 1999;27(9):1068-1073. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10460808\">[PubMed 10460808]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8844":"<p><b>Title</b> Zopiclone / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The starting adult dose of zopiclone should not exceed 3.75 mg if combined with a moderate CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity (eg, drowsiness, confusion, lethargy, ataxia, respiratory depression) if these agents are combined. If this combination is tolerated, the zopiclone dose may be increased to a maximum of 5 mg with close monitoring.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In one pharmacokinetic study, the zopiclone (7.5 mg single dose) AUC and maximum serum concentration (Cmax) increased 73% and 29%, respectively, when given after a 4-day course of the strong CYP3A4 inhibitor itraconazole (200 mg daily) in 10 healthy volunteers.<sup>1</sup> No changes in pharmacodynamic responses were seen between groups.<sup>1</sup> In another study of 10 healthy volunteers, the moderate CYP3A4 inhibitor erythromycin (500 mg three times daily for 6 days) increased the AUC and Cmax of zopiclone (7.5 mg single dose) by 80% and 40%, respectively.<sup>2</sup> A case report also describes an 86-year-old female who experienced elevated plasma levels of zopiclone along with excessive drowsiness while taking nefazodone (a strong CYP3A4 inhibitor) that resolved after nefazodone was discontinued.<sup>3</sup><br><br>Product labeling for zopiclone warns that plasma levels of zopiclone may increase if combined with CYP3A4 inhibitors since CYP3A4 is responsible for the majority of zopiclone metabolism.<sup>4,5</sup> As such, the recommended starting dose of zopiclone is 3.75 mg if used concomitantly with a moderate CYP3A4 inhibitor.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Jalava KM, Olkkola KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zopiclone. <i>Eur J Clin Pharmacol</i>. 1996;51(3-4):331-334. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9010708\">[PubMed 9010708]</a></p>\n<p>2. Aranko K, Luurila H, Backman JT, Neuvonen PJ, Olkkola KT. The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone. <i>Br J Clin Pharmacol</i>. 1994;38(4):363-367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7833227\">[PubMed 7833227]</a></p>\n<p>3. Alderman CP, Gebauer MG, Gilbert AL, Condon JT. Possible interaction of zopiclone and nefazodone. <i>Ann Pharmacother</i>. 2001;35(11):1378-1380. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11724087\">[PubMed 11724087]</a></p>\n<p>4. <i>Imovane</i> (zopiclone) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; October 2014.</p>\n<p>5. Becquemont L, Mouaijah S, Escaffre O, Beaune P, Funck-Brentano C, Jaillon P. Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. <i>Drug Metab Dispos</i>. 1999;27(9):1068-1073. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10460808\">[PubMed 10460808]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8845":"<p><b>Title</b> Zopiclone / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Zopiclone. Specifically, taking alcohol with zopiclone may increase the risk of complex sleep-related behaviors (eg, sleep-driving, eating food, making phone calls, leaving the house, etc.) Alcohol (Ethyl) may enhance the CNS depressant effect of Zopiclone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Instruct patients to avoid alcohol use while taking zopiclone.</p> \n<p><b>Discussion</b> According to product labeling, complex sleep-related behaviors (eg, sleep-driving, eating food, making phone calls, leaving the house, etc.) may occur with zopiclone alone at therapeutic doses, but the use of alcohol appears to increase the risk of such behaviors.<sup>1</sup> Additionally, because zopiclone and alcohol are both CNS depressants, and their combined use may lead to excessive CNS depression, product labeling recommends avoidance of alcohol during treatment with zopiclone.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Imovane</i> (zopiclone) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; October 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8846":"<p><b>Title</b> Dofetilide / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Dofetilide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Increase monitoring for evidence of dofetilide toxicities if used together with cobicistat. Proarrhythmic effects such as QT-prolongation and possible Torsades de Pointes are of particular concern, so closer monitoring of ECG may be warranted. Consider alternatives to this combination when possible.</p> \n<p><b>Discussion</b> Data regarding this specific combination are not available, but an interaction is anticipated based on the known properties of both drugs. Dofetilide is eliminated via glomerular filtration, active tubular secretion, and hepatic metabolism.<sup>1</sup> Inhibition of dofetilide renal tubular secretion by trimethoprim and cimetidine has been associated with up to a 103% increase in dofetilide exposure (AUC).<sup>1</sup> Consequently, concurrent use of dofetilide with inhibitors of renal cation transport is contraindicated.<sup>1</sup> Inhibition of dofetilide metabolism by CYP3A4 does not appear to have as significant of an impact on dofetilide concentrations, but caution is warranted when using dofetilide together with a CYP3A4 inhibitor.<sup>1</sup><br><br>Cobicistat is a strong inhibitor of CYP3A4 and has been shown to inhibit renal creatinine secretion via a mechanism presumed to be inhibition of the multidrug and toxin extrusion transporter 1 (MATE1).<sup>2,3</sup> The degree to which MATE1 is responsible for dofetilide excretion is unclear. Of the known inhibitors of dofetilide secretion, dolutegravir appears to inhibit the organic cation transporter 2 (OCT2), while trimethoprim and cimetidine inhibit MATE1, MATE2-K, and/or possibly other renal transporters.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tikosyn</i> (dofetilide) [prescribing information]. New York, NY: Pfizer Inc; December 2013.</p>\n<p>2. Lepist EI, Zhang X, Hao J, et al. Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. <i>Kidney Int</i>. 2014;86(2):350-357. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24646860\">[PubMed 24646860]</a></p>\n<p>3. <i>Tybost</i> (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences, Inc; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8847":"<p><b>Title</b> Etizolam / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Etizolam. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use lower etizolam doses when using this combination; specific recommendations concerning dose adjustment are not available. Monitor clinical response to the combination closely.</p> \n<p><b>Discussion</b> The average etizolam concentration was an average of 52% higher with concurrent fluvoxamine (25 mg or 50 mg daily) in a study of 18 patients treated with fluvoxamine before or after etizolam monotherapy.<sup>1</sup> A small number of patients who took larger doses of fluvoxamine were described as experiencing even greater increases in etizolam concentrations, suggesting a dose-dependency to this apparent interaction.<br><br>The exact clinical significance of this interaction is uncertain, but the labeling for etizolam recommends a decrease in dose when used with fluvoxamine due to the potential for increased concentrations.<sup>2</sup><br><br>The precise mechanism for the interaction is uncertain, but fluvoxamine is a strong inhibitor of CYP2C19 and a weak inhibitor of CYP3A4, both of which are enzymes that have been shown to be at least somewhat involved in etizolam metabolism.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Suzuki Y, Kawashima Y, Shioiri T, Someya T. Effects of concomitant fluvoxamine on the plasma concentration of etizolam in Japanese psychiatric patients: wide interindividual variation in the drug interaction. <i>Ther Drug Monit</i>. 2004;26(6):638-642. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15570188\">[PubMed 15570188]</a></p>\n<p>2. <i>Depas</i> (etizolam) [Japan Pharmaceutical Reference]. Osaka, Japan: Mitsubishi Tanabe Pharma Corporation; September 2012.</p>\n<p>3. Fukasawa T, Yasui-Furukori N, Suzuki A, Inoue Y, Tateishi T, Otani K. Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity. <i>Eur J Clin Pharmacol</i>. 2005;61(11):791-795. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16261363\">[PubMed 16261363]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8848":"<p><b>Title</b> Methocarbamol / Eperisone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Eperisone may enhance the adverse/toxic effect of Methocarbamol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for visual disturbances if eperisone is combined with methocarbamol.</p> \n<p><b>Discussion</b> According to the product labeling for eperisone, the use of methocarbamol in combination with eperisone should be done with caution.<sup>1</sup> Reports of visual disturbances have been described with the use of methocarbamol and tolperizone, a compound that is structurally analogous to eperisone.<sup>1</sup> Additionally, both methocarbamol and eperisone have been reported to cause drowsiness, lethargy, and fatigue<sup>1,2</sup>, so increased monitoring for these central nervous system adverse events may also be warranted.<br><br>The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Myonal</i> (eperisone) [summary of product characteristics]. Bunkyo-ku, Tokyo, Japan: Eisai Co Ltd; August 2014.</p>\n<p>2. <i>Robaxin</i> (methocarbamol) [prescribing information]. Milwaukee, WI: Schwarz Pharma Inc; February 2003.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8849":"<p><b>Title</b> Naloxegol / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Naloxegol. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the combination of naloxegol and St. John's wort.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the naloxegol prescribing information, naloxegol (25 mg single dose) AUC and maximum serum concentration decreased 89% and 76%, respectively, when administered following a course of rifampin (600 mg daily for multiple doses).<sup>1</sup><br><br>The likely mechanism for this interaction is rifampin induction of CYP3A4-mediated naloxegol metabolism.<sup>1</sup> As such, naloxegol prescribing information states that the use of naloxegol and strong CYP3A4 inducers (specifically citing St. John's wort as an example) is not recommended because the decreased plasma concentrations of naloxegol may result in reduced efficacy.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Movantik</i> (naloxegol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8850":"<p><b>Title</b> NIFEdipine / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of NIFEdipine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid coadministration of nifedipine with St. John's wort.</p> \n<p><b>Discussion</b> According to data in nifedipine prescribing information, the mean nifedipine AUC and maximum serum concentration (Cmax) were reduced by 97% and 95%, respectively, when nifedipine (20 mg x1) was given after 14 days of pretreatment with rifampin (600 mg/day) in a study of 12 healthy volunteers.<sup>1</sup> These findings are consistent with those of published studies of healthy volunteers that have reported several-fold increases in nifedipine clearance and substantially reduced nifedipine bioavailability when nifedipine was coadministered with rifampin.<sup>2,3</sup> Relatively similar effects on nifedipine concentrations have been observed with other drugs that are inducers of CYP3A, with concurrent phenytoin associated with an approximate 70% decrease in nifedipine AUC and concurrent St John's wort associated with a 29-48% decrease in nifedipine AUC.<sup>1,4,5,6</sup><br><br>At least 2 published case reports highlight the likely clinical significance of this interaction. In one report, a patient with previously controlled hypertension on nifedipine experienced a loss of blood pressure control after starting rifampin.<sup>7</sup> Another patient who was taking nifedipine for control of angina also experienced a loss of nifedipine effectiveness shortly after starting concurrent rifampin.<sup>8</sup><br><br>The mechanism of this interaction appears to be induction of hepatic and intestinal CYP3A4, resulting in reduced nifedipine bioavailability. Data from one study that evaluated both oral and intravenous nifedipine support the key role of intestinal CYP3A4 in this interaction, finding little evidence for a substantial change in the hepatic extraction of nifedipine (but a large increase for gut wall extraction) and only a small impact on the pharmacokinetics of intravenous nifedipine.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Adalat</i> (nifedipine) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2008.</p>\n<p>2. Ndanusa BU, Mustapha A, Abdu-Aguye I. The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. <i>J Pharm Biomed Anal</i>. 1997;15(9-10):1571-1575. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9226591\">[PubMed 9226591]</a></p>\n<p>3. Holtbecker N, Fromm MF, Kroemer HK, Ohnhaus EE, Heidemann H. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. <i>Drug Metab Dispos</i>. 1996;24(10):1121-1123. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8894514\">[PubMed 8894514]</a></p>\n<p>4. <i>Procardia</i> (nifedipine) [prescribing information]. New York, NY: Pfizer Inc; July 2013.</p>\n<p>5. <i>Procardia XL</i> (nifedipine) [prescribing information]. New York, NY: Pfizer Inc; July 2013.</p>\n<p>6. Wang XD, Li JL, Su QB, et al. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme. <i>Br J Clin Pharmacol</i>. 2009;67(2):255-261. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19173680\">[PubMed 19173680]</a></p>\n<p>7. Tada Y, Tsuda Y, Otsuka T, et al. Case report: nifedipine-rifampicin interaction attenuates the effect on blood pressure in a patient with essential hypertension. <i>Am J Med Sci</i>. 1992;303(1):25-27. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1345893\">[PubMed 1345893]</a></p>\n<p>8. Tsuchihashi K, Fukami K, Kishimoto H, et al. A case of variant angina exacerbated by administration of rifampicin. <i>Heart Vessels</i>. 1987;3(4):214-217. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3453828\">[PubMed 3453828]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8851":"<p><b>Title</b> Nilotinib / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Nilotinib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Coadministration of nilotinib with the strong CYP3A4 inducer rifampin (600mg daily x 12 days) was associated with a decrease in nilotinib AUC by approximately 80% in a study of healthy subjects.<sup>1</sup> <br><br>Due to concerns of decreased effectiveness, nilotinib prescribing information recommends avoiding concurrent use of nilotinib with strong CYP3A4 inducers.<sup>2</sup> Although the nilotinib prescribing information lists dexamethasone as a strong CYP3A4 inducer, clinical data suggests it is only a weak CYP3A4 inducer.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tanaka C, Yin OQ, Smith T, et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. <i>J Clin Pharmacol</i>. 2011;51(1):75-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20702754\">[PubMed 20702754]</a></p>\n<p>2. Tasigna (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2017.</p>\n<p>3. Stoch SA, Gargano C, Valentine J, et al. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. <i>Cancer Chemother Pharmacol</i>. 2011;67(6):1313-1321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20734049\">[PubMed 20734049]</a></p>\n<p>4. Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. <i>Pharmacol Toxicol</i>. 1998;83(3):135-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9783333\">[PubMed 9783333]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8852":"<p><b>Title</b> Nilotinib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Nilotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Nilotinib prescribing information recommends avoiding concurrent use of nilotinib with St. John's wort.</p> \n<p><b>Discussion</b> Coadministration of nilotinib with the strong CYP3A4 inducer rifampin (600mg daily x 12 days) was associated with a decrease in nilotinib AUC by approximately 80% in a study of healthy subjects.<sup>1</sup> Due to concerns of decreased effectiveness, nilotinib prescribing information recommends avoiding concurrent use of nilotinib with strong CYP3A4 inducers (St. John's wort is specifically cited as an example).<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tanaka C, Yin OQ, Smith T, et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. <i>J Clin Pharmacol</i>. 2011;51(1):75-83. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20702754\">[PubMed 20702754]</a></p>\n<p>2. <i>Tasigna</i> (nilotinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2007.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8853":"<p><b>Title</b> RomiDEPsin / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of RomiDEPsin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Though specific data are currently lacking, romidepsin prescribing information recommends avoiding concurrent use of a strong CYP3A4 inducer with romidepsin whenever possible due to the risk for decreased romidepsin concentrations and diminished clinical effectiveness.<sup>1</sup> Romidepsin is metabolized by CYP3A4, so strong CYP3A4 inducers would be expected to significantly increase romidepsin metabolism. Although romidepsin prescribing information lists dexamethasone as an example of a strong CYP3A4 inducer, the clinical data suggest it is weak CYP3A4 inducer.<sup>2,3</sup><br><br>In a clinical study summarized in romidepsin U.S. prescribing information, coadministration with rifampin actually increased the romidepsin (14 mg/m2 infused over 4 hours) maximum concentration and AUC by 60% and 80%, respectively, in patients with advanced cancer.<sup>1</sup> This may have resulted from rifampin inhibition of hepatic uptake of romidepsin, rather than the expected induction of romidepsin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Istodax (romidepsin) [prescribing information]. Summit, NJ: Celgene Corporation; July 2016.</p>\n<p>2. Stoch SA, Gargano C, Valentine J, et al. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. <i>Cancer Chemother Pharmacol</i>. 2011;67(6):1313-1321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20734049\">[PubMed 20734049]</a></p>\n<p>3. Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. <i>Pharmacol Toxicol</i>. 1998;83(3):135-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9783333\">[PubMed 9783333]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8854":"<p><b>Title</b> RomiDEPsin / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of RomiDEPsin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of St. John's wort with romidepsin when possible.</p> \n<p><b>Discussion</b> Though specific data are currently lacking, romidepsin prescribing information recommends avoiding concurrent use of a strong CYP3A4 inducer (St. John's wort is specifically cited) with romidepsin whenever possible due to the risk for decreased romidepsin concentrations and diminished clinical effectiveness.<sup>1</sup> Romidepsin is metabolized by CYP3A4, so strong CYP3A4 inducers would be expected to significantly increase romidepsin metabolism.<br><br>In a clinical study summarized in romidepsin U.S. prescribing information, coadministration with rifampin actually increased the romidepsin (14 mg/m2 infused over 4 hours) maximum concentration and AUC by 60% and 80%, respectively, in patients with advanced cancer.<sup>1</sup> This may have resulted from rifampin inhibition of hepatic uptake of romidepsin, rather than the expected induction of romidepsin metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Istodax</i> (romidepsin) [prescribing information]. Summit, NJ: Celgene Corporation; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8855":"<p><b>Title</b> SUNItinib / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of SUNItinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of sunitinib with dexamethasone when possible. If this combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.</p> \n<p><b>Discussion</b> The maximum plasma concentration and AUC of sunitinib (combined with its primary active metabolite) were decreased by 23% and 46%, respectively, when administered concomitantly with rifampin.<sup>1</sup> The likely primary mechanism of this interaction is increased CYP3A4 mediated sunitinib metabolism resulting from induction of CYP3A4. In order to avoid subtherapeutic serum concentrations of sunitinib, the prescribing information recommends avoiding such a combination when possible (specifically listing dexamethasone as a potential interacting agent), as well as consideration of increases in sunitinib dose when such combinations cannot be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sutent</i> (sunitinib) [prescribing information]. New York, NY: Pfizer Labs; May 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8857":"<p><b>Title</b> Tolvaptan / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Tolvaptan. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of strong CYP3A4 inducers with tolvaptan. If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.</p> \n<p><b>Discussion</b> In a clinical study of 15 healthy volunteers, pretreatment with rifampin (600 mg orally daily for 7 days) decreased tolvaptan (240 mg single oral dose) maximum concentration and AUC by 87% and 83%, respectively.<sup>1,2</sup> Other strong CYP3A4 inducers are expected interact in a similar manner. Since studies have not yet identified whether increased tolvaptan doses can be safely administered and maintain clinical effectiveness, such combinations of strong CYP3A4 inducers with tolvaptan should be avoided whenever possible according to tolvaptan prescribing information.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. <i>Br J Clin Pharmacol</i>. 2012;73(4):579-587. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21988334\">[PubMed 21988334]</a></p>\n<p>2. <i>Samsca</i> (tolvaptan) [prescribing information]. Tokyo, Japan: Otsuka Pharmaceutical Co Ltd; February 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8858":"<p><b>Title</b> Ulipristal / OXcarbazepine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> OXcarbazepine may decrease the serum concentration of Ulipristal. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of ulipristal in combination with oxcarbazepine. Concurrent use may result in impaired ulipristal clinical effectiveness.</p> \n<p><b>Discussion</b> In a clinical study summarized in ulipristal US prescribing information, coadministration of rifampin (600 mg daily for 9 days) decreased the maximum concentration and AUC of ulipristal acetate by 90% and 93%, respectively, and those of its active monodemethyl metabolite by 84% and 90%, respectively.<sup>1,2</sup> The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated ulipristal metabolism. Ulipristal US and Canadian product labels recommend avoiding its use in combination with any strong CYP3A4 inducer.<sup>1,2</sup> US labeling also recommends against its use in combination with several other drugs with the potential to induce CYP3A4 (e.g., bosentan, felbamate, griseofulvin, topiramate).<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>ella</i> (ulipristal acetate) [prescribing information]. Morristown, NJ: Watson Pharma, Inc; June 2014.</p>\n<p>2. <i>Fibristal</i> (ulipristal acetate) [product monograph]. Mississauga, ON: Actavis Specialty Pharmaceuticals Co; June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8859":"<p><b>Title</b> VinCRIStine (Liposomal) / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of VinCRIStine (Liposomal). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a clinical study of 15 adults with brain tumors treated with non-liposomal vincristine (2 mg intravenously), procarbazine, and lomustine, vincristine AUC was 43% lower in 9 patients who were receiving phenytoin or carbamazepine compared to patients receiving neither drug.<sup>2</sup> The likely primary mechanism of this interaction is induction of hepatic metabolism of vincristine (via CYP3A4) by carbamazepine or phenytoin. <br><br>Due to the potential for similar effects with liposomal vincristine, US prescribing information for liposomal vincristine specifically states that concomitant treatment with any strong CYP3A inducer should be avoided.<sup>2</sup> Although the prescribing information lists dexamethasone as an example of a strong CYP3A4 inducer, the clinical data suggest it is only a weak CYP3A4 inducer.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Villikka K, Kivisto KT, Maenpaa H, Joensuu H, Neuvonen PJ. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. <i>Clin Pharmacol Ther</i>. 1999;66(6):589-593. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10613614\">[PubMed 10613614]</a></p>\n<p>2. Marqibo (vincristine, liposomal) [prescribing information]. South San Francisco, CA: Talon Therapeutics Inc; August 2012.</p>\n<p>3. Stoch SA, Gargano C, Valentine J, et al. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. <i>Cancer Chemother Pharmacol</i>. 2011;67(6):1313-1321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20734049\">[PubMed 20734049]</a></p>\n<p>4. Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. <i>Pharmacol Toxicol</i>. 1998;83(3):135-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9783333\">[PubMed 9783333]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8860":"<p><b>Title</b> Vorapaxar / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Vorapaxar. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the use of vorapaxar in combination with St. John's wort.</p> \n<p><b>Discussion</b> In a clinical study of healthy volunteers, coadministration of rifampin (600 mg orally daily for 28 days) decreased the vorapaxar (20 mg orally on day 7, then 2.5 mg orally daily) final-dose maximum plasma concentration (Cmax) and AUC, by 39% and 55%, respectively.<sup>1,2</sup> Vorapaxar first-dose Cmax and AUC were unaffected. The suspected primary mechanism of this interaction is rifampin induction of CYP3A mediated vorapaxar metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Zontivity</i> (vorapaxar) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co, Inc; May 2014.</p>\n<p>2. Kosoglou T, Statkevich P, Kumar B, et al. The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar. <i>J Clin Pharmacol</i>. 2013;53(5):540-549. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23426761\">[PubMed 23426761]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8861":"<p><b>Title</b> Etizolam / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Etizolam. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider use of lower etizolam doses when using this combination; specific recommendations concerning dose adjustment are not available. Monitor clinical response to the combination closely.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The etizolam AUC was an average of 53% higher with concurrent use of the strong CYP3A4 inhibitor itraconazole in a study of 12 healthy volunteers who received a single dose of etizolam with or without concurrent itraconazole (200 mg/day for 7 days).<sup>1</sup> No changes in etizolam pharmacodynamics were found. An in vitro study using human liver microsomes similarly found that the strong CYP3A4 inhibitor ketoconazole was capable of inhibiting etizolam metabolism by more than 80%.<sup>2</sup><br><br>The exact clinical significance of this interaction is uncertain. Although management of interactions with itraconazole or other strong CYP3A4 inhibitors is not discussed in the etizolam labeling, the labeling recommends a decrease in dose when used with fluvoxamine, which was shown in one study to increase etizolam concentrations by 52%, due to the potential for increased concentrations.<sup>3</sup> Given the comparable change with itraconazole, it would seem prudent to at least consider etizolam dose reductions when used with strong inhibitors of CYP3A4.<br><br>The precise mechanism for the interaction appears to be inhibition of the CYP3A4-mediated metabolism of etizolam by itraconazole (or other strong CYP3A4 inhibitors).<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Araki K, Yasui-Furukori N, Fukasawa T, et al. Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. <i>Eur J Clin Pharmacol</i>. 2004;60(6):427-430. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15232663\">[PubMed 15232663]</a></p>\n<p>2. Niwa T, Shiraga T, Ishii I, Kagayama A, Takagi A. Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. <i>Biol Pharm Bull</i>. 2005;28(9):1711-1716. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16141545\">[PubMed 16141545]</a></p>\n<p>3. <i>Depas</i> (etizolam) [Japan Pharmaceutical Reference]. Osaka, Japan: Mitsubishi Tanabe Pharma Corporation; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8862":"<p><b>Title</b> Corifollitropin Alfa / Luteinizing Hormone-Releasing Hormone Analogs</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of luteinizing hormone-releasing hormone analogs (or gonadotropin-releasing hormone agonists) together with corifollitropin alfa is not recommended.</p>\n<div>\n <p><b>Luteinizing Hormone-Releasing Hormone Analogs Interacting Members</b> Buserelin, Goserelin, Histrelin, Leuprolide, Nafarelin, Triptorelin</p>\n</div> \n<p><b>Discussion</b> According to the corifollitropin alfa summary of product characteristics, the use of luteinizing hormone-releasing hormone analogs (or gonadotropin-releasing hormone (GnRH) agonists) together with corifollitropin alfa is not recommended.<sup>1</sup> Although there are limited data concerning the use of such a combination, the summary of product characteristics cautions that results of one small study suggests there was a greater ovarian response than that observed when corifollitropin alfa was used with a GnRH antagonist.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Elonva</i> (corifollitropin alfa) [summary of product characteristics]. Hertfordshire, United Kingdom: Merck Sharpe &amp; Dohme Limited; November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8863":"<p><b>Title</b> Itopride / Anticholinergic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anticholinergic Agents may diminish the therapeutic effect of Itopride. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor the clinical response to itopride closely, watching for evidence of diminished itopride effectiveness, with any concurrent use of anticholinergic agents.</p>\n<div>\n <p><b>Anticholinergic Agents Interacting Members</b> Aclidinium, Acrivastine, Amitriptyline, Amoxapine, Atropine (Ophthalmic), Atropine (Systemic), Belladonna, Benperidol, Benztropine, Bilastine, Biperiden, Bromperidol, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, ChlorproMAZINE, Cimetropium, Clemastine, Clidinium, ClomiPRAMINE, CloZAPine, Cyclizine, Cyclobenzaprine, Cyclopentolate, Cyproheptadine, Darifenacin, Desipramine, Dexbrompheniramine, Dexchlorpheniramine, Dicyclomine, DimenhyDRINATE, DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Disopyramide, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Doxylamine, Droperidol, Ebastine, Fesoterodine, Fexofenadine, FlavoxATE, Flupentixol, FluPHENAZine, Glycopyrrolate (Oral Inhalation), Glycopyrrolate (Systemic), Haloperidol, Homatropine, HydrOXYzine, Hyoscyamine, Imidafenacin, Imipramine, Ipratropium (Nasal), Ipratropium (Oral Inhalation), Isocarboxazid, Ketotifen (Systemic), Levocetirizine, Lofepramine, Loratadine, Loxapine, Maprotiline, Meclizine, Melitracen [INT], Mepenzolate, Mequitazine, Methotrimeprazine, Methscopolamine, Methylene Blue, Moclobemide, Molindone, Nefopam, Nortriptyline, OLANZapine, Olopatadine (Systemic), Orphenadrine, Oxatomide, Oxomemazine, Oxybutynin, Periciazine, Perphenazine, Phenelzine, Pheniramine, Phenyltoloxamine, Pimozide, Pizotifen, Prifinium, Prochlorperazine, Procyclidine, Promazine, Promethazine, Propantheline, Propiverine, Protriptyline, Pyrilamine (Systemic), QUEtiapine, QuiNIDine, RisperiDONE, Rupatadine, Scopolamine (Ophthalmic), Scopolamine (Systemic), Solifenacin, Syrian Rue, Thioridazine, Thiothixene, Thonzylamine, Tiotropium, Tiropramide, Tolterodine, Tranylcypromine, Trifluoperazine, Trihexyphenidyl, Trimeprazine, Trimethobenzamide, Trimipramine, Triprolidine, Trospium, Umeclidinium, Zuclopenthixol</p>\n</div> \n<p><b>Discussion</b> The labeling for itopride cautions that concurrent use of anticholinergic agents may decrease the therapeutic effect of itopride by interfering with its mechanism of action.<sup>1</sup> Specific data concerning use of such a combination are not available.<br><br>Itopride enhances the actions of acetylcholine by increasing the release of acetylcholine and by interfering with the metabolism of acetylcholine,<sup>1</sup> thus drugs that antagonize acetylcholine actions may interfered with the clinical effects of itopride.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ganaton</i> (itopride) [Japan Pharmaceutical Reference]. Matsudo City, Chiba, Japan: Abbott Japan Co., Ltd.; May 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8864":"<p><b>Title</b> CYP1A2 Substrates (High risk with Inhibitors) / Peginterferon Alfa-2b</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Peginterferon Alfa-2b may increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for potential toxicity of CYP1A2 substrates, particularly those considered to have a narrow therapeutic range, when used with peginterferon alfa-2b.</p>\n<div>\n <p><b>CYP1A2 Substrates (High risk with Inhibitors) Interacting Members</b> Acebrophylline, Acenocoumarol, Agomelatine, Alosetron, Aminophylline, Asenapine, Bromazepam, Caffeine, ClomiPRAMINE, CloZAPine, Cyclobenzaprine, Dacarbazine, DULoxetine, Flutamide, FluvoxaMINE, Kola Nut, Lidocaine (Systemic), Lidocaine (Topical), Melatonin, Mexiletine, Mirtazapine, OLANZapine, Pimozide, Pirfenidone, Pomalidomide, Propranolol, Ramelteon, Ramosetron, Rasagiline, ROPINIRole, Ropivacaine, Stiripentol, Tasimelteon, Theophylline, Thiothixene, TiZANidine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 22 patients with hepatitis C, summarized in peginterferon alfa-2b US prescribing information, treatment with peginterferon alfa-2b (1.5 mcg/kg weekly for 4 weeks) increased the caffeine AUC 39% and decreased the caffeine oral clearance 32%.<sup>1,2</sup> In clinical studies of healthy volunteers, peginterferon alfa-2b (1 mcg/kg weekly for 4 weeks) and peginterferon alfa-2b (3 mcg/kg weekly for 2 weeks) increased the caffeine AUC 18% and 36%, respectively.<sup>1</sup><br><br>The mechanism of this possible interaction is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>PegIntron</i> (peginterferon alfa-2b) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; September 2015.</p>\n<p>2. Gupta SK, Kolz K, Cutler DL. Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. <i>Eur J Clin Pharmacol</i>. 2011;67(6):591-599. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21161196\">[PubMed 21161196]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8880":"<p><b>Title</b> Bortezomib / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Bortezomib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the bortezomib prescribing information, the coadministration of dexamethasone (40 mg daily on days 1 to 4 and 9 to 12) with bortezomib (1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11) during one cycle of chemotherapy resulted in no change in the AUC of bortezomib compared with the administration of bortezomib alone during another cycle of chemotherapy in 7 patients.<sup>1,2</sup><br><br>Bortezomib is a CYP3A4 substrate and dexamethasone is a moderate inducer of CYP3A4. The lack of an observed interaction may relate to the dosing regimen of dexamethasone, as the effect of continuous daily dosing of dexamethasone on bortezomib exposure is unknown. Alternatively, because bortezomib is metabolized by other cytochrome isoenzymes (eg, CYP2C19, CYP1A2) moderate induction of CYP3A4 by dexamethasone may not result in a significant change in exposure.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Velcade</i> (bortezomib) [prescribing information]. Cambridge, MA: Millennium Pharmaceuticals Inc; October 2014.</p>\n<p>2. Hellmann A, Rule S, Walewski J, et al. Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. <i>Clin Pharmacokinet</i>. 2011;50(12):781-791. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22087865\">[PubMed 22087865]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8882":"<p><b>Title</b> Dasatinib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dasatinib. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of dasatinib with strong inhibitors of CYP3A4 should be avoided; consider an alternative to the strong inhibitor when possible. If such a combination must be used, consider a reduction in the dasatinib dose. Although specific data concerning potential dose adjustments are not available, the dasatinib prescribing information recommends that if patients are using dasatinib 70 mg/day or 100 mg/day, consider a reduction to 20 mg/day; and if patients are using dasatinib 140 mg/day, consider a reduction to 40 mg/day. Monitor patient response to the combination closely, and make any further dose adjustments as necessary.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The average dasatinib AUC and maximum serum concentration were 4.8- and 3.6-fold higher, respectively, with concurrent use of the strong CYP3A4 inhibitor ketoconazole in a study of patients with advanced solid tumors who received dasatinib 20 mg/day for 8 days together with ketoconazole 200 mg twice/day (on days 3 to 8).<sup>1</sup><br><br>According to the dasatinib prescribing information, concurrent use of dasatinib with strong inhibitors of CYP3A4 should be avoided.<sup>2</sup> If such a combination must be used, consider a reduction in the dasatinib dose. Although specific data concerning potential dose adjustments are not available, the dasatinib prescribing information recommends that if patients are using dasatinib 100 mg/day, consider a reduction to 20 mg/day, and if patients are using dasatinib 140 mg/day, consider a reduction to 40 mg/day. Monitor patient response to the combination closely, and make any further dose adjustments as necessary.<sup>2</sup><br><br>The likely mechanism for this interaction is inhibition of the CYP3A4-mediated metabolism of dasatinib. Dasatinib is primarily metabolized by CYP3A4,<sup>2</sup> and ketoconazole is a strong inhibitor of CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. <i>Cancer</i>. 2010;116(6):1582-1591. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20108303\">[PubMed 20108303]</a></p>\n<p>2. Sprycel (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8883":"<p><b>Title</b> Dasatinib / Voriconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Voriconazole may enhance the QTc-prolonging effect of Dasatinib. Voriconazole may increase the serum concentration of Dasatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of dasatinib with voriconazole should be avoided; consider an alternative to voriconazole when possible. If this combination must be used, consider a reduction in the dasatinib dose. Although specific data concerning potential dose adjustments are not available, the dasatinib prescribing information recommends that if patients are using dasatinib 100 mg/day, consider a reduction to 20 mg/day, and if patients are using dasatinib 140 mg/day, consider a reduction to 40 mg/day. Monitor patient response to the combination closely, and make any further dose adjustments as necessary. Close monitoring of ECG for QT prolongation and new arrhythmias is also warranted with use of this combination.</p> \n<p><b>Discussion</b> The average dasatinib AUC and maximum serum concentration were 4.8- and 3.6-fold higher, respectively, with concurrent use of the strong CYP3A4 inhibitor ketoconazole in a study of patients with advanced solid tumors who received dasatinib 20 mg/day for 8 days together with ketoconazole 200 mg twice/day (on days 3 to 8).<sup>1</sup> According to the dasatinib prescribing information, concurrent use of dasatinib with strong inhibitors of CYP3A4 should be avoided.<sup>2</sup> If such a combination must be used, consider a reduction in the dasatinib dose. Although specific data concerning potential dose adjustments are not available, the dasatinib prescribing information recommends that if patients are using dasatinib 100 mg/day, consider a reduction to 20 mg/day, and if patients are using dasatinib 140 mg/day, consider a reduction to 40 mg/day. Monitor patient response to the combination closely, and make any further dose adjustments as necessary.<sup>2</sup><br><br>The likely mechanism for this interaction is inhibition of the CYP3A4-mediated metabolism of dasatinib. Dasatinib is primarily metabolized by CYP3A4,<sup>2</sup> and ketoconazole is a strong inhibitor of CYP3A4.<br><br>An additional consideration with this potential interaction is that both dasatinib and voriconazole have a potential to prolong the QT interval, which could increase the risk for serious arrhythmias such as Torsade de Pointes (TdP).<sup>2,3</sup> Since increased drug concentration and use with other QT-prolonging medications are suspected risk factors for clinically relevant consequences of this interaction, such as TdP, the expected pharmacokinetic interaction between these agents together with each medication's potential for QT interval-prolongation are likely to increase the risk of clinically significant prolongation of the QT interval with this combination.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. <i>Cancer</i>. 2010;116(6):1582-1591. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20108303\">[PubMed 20108303]</a></p>\n<p>2. <i>Sprycel</i> (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; April 2014.</p>\n<p>2. <i>Vfend</i> (voriconazole) [prescribing information]. New York, NY: Pfizer Inc; February 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8884":"<p><b>Title</b> Cabazitaxel / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabazitaxel. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Concurrent use of cabazitaxel with strong inhibitors of CYP3A4 should be avoided when possible. If such a combination must be used, consider a 25% reduction in the cabazitaxel dose. Monitor patient response to the combination closely.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> The average cabazitxel AUC was 1.25-fold higher (90% CI: 0.86 to 1.81) with concurrent use of the strong CYP3A4 inhibitor ketoconazole in a study of 23 patients with advanced cancer who received cabazitaxel 5 mg/m<sup>2</sup> IV together with ketoconazole 400 mg/day.<sup>1</sup> According to the cabazitaxel prescribing information, concurrent use of cabazitaxel with strong inhibitors of CYP3A4 should be avoided.<sup>2</sup> If such a combination must be used, consideration of a 25% reduction in the cabazitaxel dose is recommended.<sup>2</sup><br><br>The likely mechanism for this interaction is inhibition of the CYP3A4-mediated metabolism of cabazitaxel. Cabazitaxel is primarily metabolized by CYP3A4,<sup>2</sup> and ketoconazole is a strong inhibitor of CYP3A4.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sarantopoulos J, Mita AC, Wade JL, et al. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel. <i>Cancer Chemother Pharmacol</i>. 2014;74(6):1113-1124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25307552\">[PubMed 25307552]</a></p>\n<p>2. <i>Jevtana</i> (cabazitaxel) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8885":"<p><b>Title</b> GuanFACINE / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the CNS depressant effect of GuanFACINE. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid consuming alcohol while taking guanfacine.</p> \n<p><b>Discussion</b> The guanfacine prescribing information recommends advising patients not to consume alcohol while receiving guanfacine.<sup>1</sup> Somnolence and sedation are commonly reported adverse effects associated with guanfacine use.<sup>1</sup> Concurrent use of alcohol could be expected to increase the CNS depressant effects of guanfacine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Intuniv</i> (guanfacine) [prescribing information]. Wayne, PA: Shire US Inc.; November 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8886":"<p><b>Title</b> Cannabidiol / St John's Wort</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: UK product labeling for tetrahydrocannabinol/cannabidiol oromucosal spray recommends avoiding use of this product in combination with strong CYP3A4 inducers and St Johns Wort. Labeling in other areas may differ (eg, Canadian labeling gives no specific management recommendation).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Cannabidiol. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients who use cannabidiol (CBD) in combination with St Johns Wort closely for reduced systemic CBD effects.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, coadministration of rifampin (600 mg daily x 10 days) and 4 sprays of the tetrahydrocannabinol and cannabidiol (CBD) oromucosal spray decreased the maximum concentration (Cmax) and AUC of CBD by 51% and 58%, respectively.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated metabolism of CBD.<sup>2</sup> Since St Johns Wort is also a CYP3A4 inducer, similar caution is warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sativex</i> (tetrahydrocannabinol and cannabidiol oromucosal spray) [U.K. summary of product characteristics]. Wiltshire, U.K.: GW Pharma Ltd; February 2014.</p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8887":"<p><b>Title</b> Cannabis / St John's Wort</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is mainly expected to reduce systemic concentrations and effects of tetrahydrocannabinol and cannabidiol. Patients using a cannabis strain, product, or route of administration that does not introduce physiologically significant amounts of these compounds may not be affected.</p></li>\n <li><p><b>International labeling</b>: UK product labeling for tetrahydrocannabinol/cannabidiol oromucosal spray recommends avoiding use of this product in combination with strong CYP3A4 inducers and St Johns Wort. Labeling in other areas may differ (eg, Canadian labeling gives no specific management recommendation).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Cannabis. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients who use cannabis in combination with St Johns Wort closely for reduced systemic effects of tetrahydrocannabinol (THC) and cannabidiol (CBD). No significant interaction has been described between CYP3A4 inducers and cannabis strains/products/uses that do not introduce substantial systemic THC or CBD concentrations.</p> \n<p><b>Discussion</b> In a clinical study summarized in the U.K. summary of product characteristics for tetrahydrocannabinol (THC) and cannabidiol (CBD) oromucosal spray, coadministration of rifampin decreased the maximum concentration (Cmax) and AUC of THC by 40% and 20%, respectively, while the Cmax and AUC of its primary hydroxylated metabolite were reduced by 85% and 87%, respectively.<sup>1</sup> The Cmax and AUC of CBD decreased by 50% and 60%, respectively.<br><br>The suspected primary mechanism of this interaction is rifampin induction of CYP3A4 mediated metabolism of THC and CBD. Since St Johns Wort is also capable of inducing CYP3A4, similar caution is warranted. Rifampin induction of other pathways, particularly CYP2C9 for THC, also likely contributes. Systemic exposure to THC and CBD administered via other routes (e.g., oral, inhaled) is also expected to increase with coadministration of a CYP3A4 inducer. Cannabinol (another cannabinoid commonly found in cannabis and cannabis products) may also be metabolized by CYP3A4, although the significance of this to the clinical effects of cannabis has not been investigated.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sativex</i> (tetrahydrocannabinol and cannabidiol oromucosal spray) [U.K. summary of product characteristics]. Wiltshire, U.K.: GW Pharma Ltd; February 2014.</p>\n<p>2. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. <i>Life Sci</i>. 2007;80(15):1415-1419. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17303175\">[PubMed 17303175]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8888":"<p><b>Title</b> CloZAPine / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of CloZAPine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Clozapine prescribing information does not recommend concurrent use with St. John’s wort, but if the combination is necessary, increased clozapine doses may be required. Patient response to the combination should be closely monitored. Clozapine dose reduction and further monitoring may also be required upon discontinuation of St. John’s wort in patients who had been maintained on the combination.</p> \n<p><b>Discussion</b> Clozapine prescribing information does not recommend concurrent use with St. John’s wort, but if the combination is necessary, increased clozapine doses may be required.<sup>1</sup> Because clozapine is metabolized by CYP1A2 (primarily), CYP2D6, and CYP3A4, its concurrent use with enzyme inducers such as St. John’s wort is expected to lead to reduced clozapine concentrations due to enhanced elimination.<sup>1</sup><br><br>Case reports with the inducers carbamazepine and St John's wort describe reduced clozapine concentrations (47% to 50% reductions in concentration or concentration/dose ratio) and worsening of psychiatric symptoms.<sup>2,3,4</sup> Another report describes a significant increase in clozapine concentrations and adverse effects following a change from carbamazepine to oxcarbazepine, an antiepileptic associated with less CYP3A4 induction.<sup>5</sup><br><br>Similarly, reports with the inducers phenytoin and rifampin describe reduced clozapine concentrations and effectiveness with concurrent therapy.<sup>6,7,8</sup><br><br>Of note, some reports have suggested that concurrent use of clozapine with enzyme inducers such as carbamazepine may also be associated with a greater risk for clozapine adverse effects,<sup>9,10</sup> an effect that may be related to the relatively greater concentration of metabolites such as norclozapine.<sup>11</sup> The true clinical significance of any such shift in metabolite concentrations is unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Clozaril</i> (clozapine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2014.</p>\n<p>2. Van Strater AC, Bogers JP. Interaction of St Johns wort (hypericum perforatum) with clozapine. <i>Int Clin Psychopharmacol</i>. 2012;27(2):121-124. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22113252\">[PubMed 22113252]</a></p>\n<p>3. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. <i>Pharmacopsychiatry</i>. 1995;28(1):26-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7746842\">[PubMed 7746842]</a></p>\n<p>4. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. <i>Ther Drug Monit</i>. 1994;16(4):368-374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7974626\">[PubMed 7974626]</a></p>\n<p>5. Raitasuo V, Lehtovaara R, Huttunen MO. Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics. A case report. <i>Psychopharmacology (Berl)</i>. 1994;116(1):115-116. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7862923\">[PubMed 7862923]</a></p>\n<p>6. Miller DD. Effect of phenytoin on plasma clozapine concentrations in two patients. <i>J Clin Psychiatry</i>. 1991;52(1):23-25. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1988414\">[PubMed 1988414]</a></p>\n<p>7. Peritogiannis V, Pappas D, Antoniou K, Hyphantis T, Mavreas V. Clozapine-rifampicin interaction in a patient with pulmonary tuberculosis. <i>Gen Hosp Psychiatry</i>. 2007;29(3):281-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17484952\">[PubMed 17484952]</a></p>\n<p>8. Joos AA, Frank UG, Kaschka WP. Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection. <i>J Clin Psychopharmacol</i>. 1998;18(1):83-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9472849\">[PubMed 9472849]</a></p>\n<p>9. Muller T, Becker T, Fritze J. Neuroleptic malignant syndrome after clozapine plus carbamazepine. <i>Lancet</i>. 1988;2(8626-8627):1500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2904624\">[PubMed 2904624]</a></p>\n<p>10. Junghan U, Albers M, Woggon B. Increased risk of hematological side-effects in psychiatric patients treated with clozapine and carbamazepine? <i>Pharmacopsychiatry</i>. 1993;26(6):262. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8127933\">[PubMed 8127933]</a></p>\n<p>11. Langbehn DR, Alexander B. Increased risk of side-effects in psychiatric patients treated with clozapine and carbamazepine: a reanalysis. <i>Pharmacopsychiatry</i>. 2000;33(5):196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11071023\">[PubMed 11071023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8889":"<p><b>Title</b> Dasatinib / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Dasatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of dasatinib with dexamethasone when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitoring clinical response and toxicity closely.</p> \n<p><b>Discussion</b> In a clinical study described in dasatinib prescribing information, dasatinib (100 mg single oral dose) AUC decreased by 82% in 20 healthy volunteers when administered following an 8-day course of rifampin (600 mg/day).<sup>1</sup> <br><br>The likely primary mechanism of this interaction is rifampin induction of CYP3A4 mediated dasatinib metabolism. In order to avoid subtherapeutic serum concentrations of dasatinib, the prescribing information recommends avoiding combinations with CYP3A4 inducers, listing dexamethasone as an example of an inducer to avoid.<sup>1</sup> When such combinations cannot be avoided, increasing the dasatinib dose should be considered.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Sprycel</i> (dasatinib) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; October 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8890":"<p><b>Title</b> Dienogest / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Dienogest. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of dienogest for contraception when using St Johns Wort, or any medication that induces CYP3A4, and for at least 28 days after discontinuation of the St Johns Wort. An alternative form of contraception should be used during this time.</p> \n<p><b>Discussion</b> Dienogest AUC was an average of 83% lower following 5 days of concurrent rifampin (600 mg/d) in a study of 16 healthy, postmenopausal women.<sup>1</sup> The average dienogest maximum serum concentration (Cmax) was reduced by 52%. Considering data such as these, estradiol valerate/dienogest prescribing information recommends avoiding use of this product with CYP3A4 inducers, including St Johns Wort, as well as for at least 28 days following discontinuation.<sup>1</sup><br><br>The mechanism of this potential interaction appears to be increased dienogest CYP3A4-mediated metabolism by St Johns Wort.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Natazia</i> (estradiol valerate and estradiol valerate/dienogest) [prescribing information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc; May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8891":"<p><b>Title</b> DOXOrubicin (Conventional) / St John's Wort</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: US labeling for doxorubicin from one manufacturer (Pfizer) recommends avoiding the combination of St Johns Wort and doxorubicin.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of DOXOrubicin (Conventional). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Seek alternatives to St Johns Wort in patients treated with doxorubicin whenever possible. One US manufacturer (Pfizer) recommends that this combination be avoided.</p> \n<p><b>Discussion</b> US prescribing information for doxorubicin from one manufacturer (Pfizer), warns that its use in combination with inhibitors or inducers of CYP3A4 (such as St Johns Wort), CYP2D6, or P-glycoprotein (P-gp) should be avoided due to the potential for increased doxorubicin systemic exposure and effects.<sup>1</sup> Prescribing information for doxorubicin from another manufacturer (Bedford Laboratories), in contrast, describes several interactions potentially related to these mechanisms but offers no general recommendations for modification of therapy.<sup>2</sup> <br><br>Doxorubicin is a substrate of CYP3A4, CYP2D6, and P-gp, so modification of any of these pathways could theoretically increase doxorubicin exposure and systemic effects.<sup>1</sup> However, clinical data characterizing the relative importance of these pathways and the impact of their modulation on doxorubicin exposure and effects are scarce. Additionally, projection of clinical risk based on pharmacokinetic properties or data alone is complicated by the potential for expression of enzymes and transporters (including those listed) to act as resistance mechanisms in tumor cells as well as protective mechanisms in non-tumor tissues (including the heart).<sup>3</sup><br><br>In one clinical study, intravenous coadministration of the P-gp inhibitor zosquidar at doses of 500 mg or greater increased the AUC of doxorubicin by 15%-25% and decreased apparent clearance of its active metabolite doxorubicinol by an estimated 48%.<sup>4,5</sup> The P-gp inhibitor progesterone, administered by continuous intravenous infusion, increased the hematologic toxicity of doxorubicin without affecting systemic exposure to either doxorubicin or doxorubicinol in another study.<sup>6</sup> Cyclosporine, an inhibitor of P-gp and a moderate inhibitor of CYP3A4, increased AUCs of doxorubicin and doxorubicinol by 48% and 443%, respectively, and increased myelotoxicity in a small study of patients with small cell lung cancer.<sup>7</sup> Several other clinical studies have similarly reported increased doxorubicin toxicity, significant increases in doxorubicin concentrations, and/or reduced doxorubicin dose requirements with concurrent cyclosporine use.<sup>8,9,10,11</sup> Ketoconazole (a strong CYPA4 inhibitor and P-gp inhibitor) was also used with doxorubicin in one pilot study, but no pharmacokinetic data or comparisons to doxorubicin alone are available.<sup>12</sup><br><br>Other available data are less clear as to the interaction potential when doxorubicin is used with inhibitors or inducers of CYP3A4, CYP2D6, or P-gp. In one retrospective analysis, 24 patients with non-Hodgkin lymphoma (NHL) who received “CHOP” chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) in combination with an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (saquinavir, indinavir, ritonavir, or nevirapine/ritonavir) had a greater incidence of grade 3-4 anemia (33% vs. 7%) and severe autonomic neurotoxicity (17% vs. 0%) than 80 patients who received similar chemotherapy regimens without protease inhibitors.<sup>13</sup> In a subsequent crossover study of 19 patients with HIV and NHL, however, use of an antiretroviral regimen containing a CYP3A4 inhibiting protease inhibitor (indinavir, saquinavir, or nelfinavir) during CHOP chemotherapy was associated with no difference in doxorubicin maximum concentration or AUC compared to CHOP chemotherapy alone.<sup>14</sup> The potential impact on doxorubicinol exposure was not investigated. Finally, one pharmacogenetic study described a roughly 16% decrease in doxorubicin clearance in individuals carrying alleles associated with lower pregnane X receptor (PXR) associated CYP3A4 and P-gp expression,<sup>15</sup> while a separate pharmacogenetic study found no correlation between doxorubicin pharmacokinetic variants and variants in genes coding for PXR and 2 functionally related nuclear receptors (constitutive androstane receptor and hepatocyte nuclear factor 4 alpha).<sup>16</sup><br><br>Based on published datal, the concomitant use of at least some inhibitors of P-gp and/or CYP3A4 likely increases doxorubicin exposure and the risk of some toxicities. The potential impact of induction of these enzymes or inhibition of CYP2D6 on doxorubicin exposure and effects has not been well characterized clinically.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Doxorubicin [prescribing information]. New York, NY: Pfizer Inc; October 2013.</p>\n<p>2. <i>Adriamycin</i> (doxorubicin) [prescribing information]. Bedford, OH: Bedford Laboratories; July 2012.</p>\n<p>3. McCaffrey TA, Tziros C, Lewis J, et al. Genomic profiling reveals the potential role of TCL1A and MDR1 deficiency in chemotherapy-induced cardiotoxicity. <i>Int J Biol Sci</i>. 2013;9(4):350-360. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23630447\">[PubMed 23630447]</a></p>\n<p>4. Sandler A, Gordon M, De Alwis DP, et al. A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. <i>Clin Cancer Res</i>. 2004;10(10):3265-3272. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15161679\">[PubMed 15161679]</a></p>\n<p>5. Callies S, de Alwis DP, Wright JG, Sandler A, Burgess M, Aarons L. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). <i>Cancer Chemother Pharmacol</i>. 2003;51(2):107-118. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12647011\">[PubMed 12647011]</a></p>\n<p>6. Christen RD, McClay EF, Plaxe SC, et al. Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin. <i>J Clin Oncol</i>. 1993;11(12):2417-2426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8246031\">[PubMed 8246031]</a></p>\n<p>7. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. <i>Cancer</i>. 1994;74(3):834-841. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8039111\">[PubMed 8039111]</a></p>\n<p>8. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. <i>Cancer Res</i>. 1993;53(20):4837-4842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8402670\">[PubMed 8402670]</a></p>\n<p>9. Tidefelt U, Juliusson G, Elmhorn-Rosenborg A, Peterson C, Paul C. Increased intracellular concentrations of doxorubicin in resistant lymphoma cells in vivo by concomitant therapy with verapamil and cyclosporin A. <i>Eur J Haematol</i>. 1994;52(5):276-282. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8020627\">[PubMed 8020627]</a></p>\n<p>10. Bartlett NL, Lum BL, Fisher GA, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. <i>J Clin Oncol</i>. 1994;12(4):835-842. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8151326\">[PubMed 8151326]</a></p>\n<p>11. Sonneveld P, Suciu S, Weijermans P, et al; European Organization for Research and Treatment of Cancer (EORTC); Leukaemia Cooperative Group (LCG); Dutch Haemato-Oncology Cooperative Study Group (HOVON). Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). <i>Br J Haematol</i>. 2001;115(4):895-902. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11843823\">[PubMed 11843823]</a></p>\n<p>12. Sella A, Kilbourn R, Amato R, et al. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. <i>J Clin Oncol</i>. 1994;12(4):683-688. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7512126\">[PubMed 7512126]</a></p>\n<p>13. Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. <i>Cancer</i>. 2001;91(1):155-163. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11148572\">[PubMed 11148572]</a></p>\n<p>14. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. <i>Ann Oncol</i>. 2004;15(12):1805-1809. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15550586\">[PubMed 15550586]</a></p>\n<p>15. Sandanaraj E, Lal S, Selvarajan V, et al. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. <i>Clin Cancer Res</i>. 2008;14(21):7116-7126. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18981011\">[PubMed 18981011]</a></p>\n<p>16. Hor SY, Lee SC, Wong CI, et al. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. <i>Pharmacogenomics J</i>. 2008;8(2):139-146. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17876342\">[PubMed 17876342]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8892":"<p><b>Title</b> Erlotinib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Erlotinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of erlotinib with St Johns Wort when possible. If such a combination cannot be avoided, the erlotinib prescribing information recommends increasing the erlotinib dose by 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg/day.</p> \n<p><b>Discussion</b> The erlotinib AUC was reduced by an average of 67% to 81% with concomitant administration of rifampin (600 mg/day for 7 to 11 days), a strong CYP3A4 inducer, in two separate studies in healthy volunteers.<sup>1</sup> Similarly, an in vitro study conducted in cultured hepatocytes found that clearance of erlotinib was increased approximately 2-fold by rifampin and the moderate CYP3A4 inducer efavirenz.<sup>2</sup> As a result of this apparent interaction, the erlotinib prescribing information recommends avoiding the combination of erlotinib and CYP3A4 inducers, including St Johns Wort, when possible.<sup>3</sup> When the combination must be used, increasing the erlotinib dose by 50 mg increments at 2 week intervals as tolerated, to a maximum of 450 mg/day is suggested.<sup>3</sup><br><br>The likely mechanism for this interaction is increased CYP3A-mediated metabolism of erlotinib, as erlotinib metabolism is primarily mediated by CYP3A4 with some additional contribution by CYP1A2.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hamilton M, Wolf JL, Drolet DW, et al. The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects. <i>Cancer Chemother Pharmacol</i>. 2014;73(3):613-621. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24474302\">[PubMed 24474302]</a></p>\n<p>2. Pillai VC, Venkataramanan R, Parise RA, et al. Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. <i>Drug Metab Dispos</i>. 2013;41(10):1843-1851. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23913028\">[PubMed 23913028]</a></p>\n<p>3. <i>Tarceva</i> (erlotinib) [prescribing information]. Northbrook, IL: OSI Pharmaceuticals LLC; April 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8893":"<p><b>Title</b> Lapatinib / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Lapatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of dexamethasone should generally be avoided during treatment with lapatinib. If an overlap in therapy cannot be avoided, consider titrating lapatinib dose gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor positive, HER2 positive breast cancer) based on tolerability (note: this dose adjustment recommendation is based on pharmacokinetic studies with lapatinib; its impact on safety and efficacy is unknown).</p> \n<p><b>Discussion</b> In a clinical study described in lapatinib prescribing information, coadministration of carbamazepine (titrated to 200 mg orally twice daily over 20 days) decreased the maximum concentration (Cmax) and AUC of lapatinib (250 mg single oral dose) by 59% and 72%, respectively, in 22 healthy volunteers.<sup>1,2</sup> <br><br>The mechanism of this interaction is likely at least twofold: 1) carbamazepine induction of CYP3A4 mediated lapatinib metabolism; and 2) carbamazepine induction of P-glycoprotein mediated lapatinib transport. Both of these mechanisms would be expected to decrease lapatinib Cmax and AUC. Since dexamethasone is also a CYP3A4 inducer, prescribing information for lapatinib recommends avoidance of dexamethasone if possible.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Tykerb</i> (lapatinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2011.</p>\n<p>2. Smith DA, Koch KM, Arya N, Bowen CJ, Herendeen JM, Beelen A. Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects. <i>Br J Clin Pharmacol</i>. 2009;67(4):421-426. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19371315\">[PubMed 19371315]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8894":"<p><b>Title</b> Ixabepilone / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Ixabepilone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of dexamethasone with ixabepilone should be avoided whenever possible. If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.</p> \n<p><b>Discussion</b> According to ixabepilone prescribing information, the mean ixabepilone AUC was 43% lower with concurrent use of the strong CYP3A4 inducer rifampin.<sup>1</sup> As a result, it is recommended that the use of a CYP3A4 inducer, such as dexamethasone, with ixabepilone should be avoided whenever possible. When such a combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<sup>1</sup> The prescribing information notes that this dosing recommendation is extrapolated from a pharmacokinetic study with rifampin and is not supported by any specific clinical trial data.<br><br>The likely mechanism of this interaction is induction of the CYP3A4-mediated metabolism of ixabepilone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Ixempra</i> (ixabepilone) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8895":"<p><b>Title</b> Imatinib / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Imatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concurrent use of imatinib with dexamethasone when possible. If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.</p> \n<p><b>Discussion</b> The AUC of imatinib (400 mg single dose) was decreased 74% in 14 healthy subjects when administered following an 8-day course of rifampin (600 mg/day).<sup>1</sup> Similarly, as summarized in the imatinib prescribing information, a study of patients receiving enzyme inducing antiepileptic drugs (eg, phenytoin, carbamazepine) found that the dose-normalized AUC of imatinib was an average of 73% lower as compared to that of similar patients not receiving such enzyme-inducing agents.<sup>2</sup><br><br>The likely mechanism for this interaction is increased imatinib CYP3A4-mediated metabolism resulting from induction of CYP3A4.<sup>1,2</sup> Dexamethasone is specifically listed in the imatinib prescribing information as a medication that may interact with imatinib via this mechanism,<sup>2</sup> While dexamethasone does have the potential to induce CYP3A4, the strength of inhibition is usually considered weak to moderate,<sup>3,4,5</sup> making the need for an imatinib dose adjustment uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, ST1571) in healthy subjects. <i>Cancer Chemother Pharmacol</i>. 2004;53(2):102-106. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14605865\">[PubMed 14605865]</a></p>\n<p>2. Gleevec (imatinib) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2016.</p>\n<p>3. Stoch SA, Gargano C, Valentine J. Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. <i>Cancer Chemother Pharmacol</i>. 2011;67(6):1313-1321. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20734049\">[PubMed 20734049]</a></p>\n<p>4. Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. <i>Pharmacol Toxicol</i>. 1998;83(3):135-138. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9783333\">[PubMed 9783333]</a></p>\n<p>5. Decadron (dexamethasone) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; May 2004.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8896":"<p><b>Title</b> Exemestane / St John's Wort</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Dosing recommendations differ between US and Canadian labels. US labeling recommends a dose increase (50 mg/day) in patients receiving St Johns Wort. The Canadian product labeling does not recommend a dose adjustment with this combination.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Exemestane. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Exemestane US product labeling recommends using an increased dose (50 mg/day) in patients receiving St Johns Wort and other strong CYP3A4 inducers. Monitor patients closely for evidence of toxicity and/or inadequate clinical response. Exemestane Canadian product monograph does not recommend a dose increase with concurrent use of any CYP3A4 inducers.</p> \n<p><b>Discussion</b> The exemestane AUC was decreased an average of 54% in 10 healthy postmenopausal female volunteers when exemestane (25 mg single dose) was given following a 14-day course of the strong CYP3A4 inducer rifampin (600 mg/day).<sup>1</sup><br><br>The likely mechanism of this interaction is rifampin-mediated induction of exemestane metabolism via CYP3A4.<br><br>Exemestane US product labeling recommends using an increased exemestane dose of 50 mg/day when used with rifampin, other strong CYP3A4 inducers, or St Johns Wort.<sup>1</sup> Exemestane Canadian product monograph acknowledges the pharmacokinetic interaction with strong CYP3A4 inducers but suggests that the suppression of plasma estrogen by exemestane is not affected and does not recommend a dose increase.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Aromasin</i> (exemestane) [prescribing information]. New York, NY: Pfizer Inc; March 2011.</p>\n<p>2. <i>Aromasin</i> (exemestane) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; January 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8897":"<p><b>Title</b> Axitinib / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of axitinib with a moderate CYP3A4 inducer should be avoided when possible. If any such combination is necessary, monitor for reduced axitinib efficacy.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> Axitinib AUC and maximum serum concentration (Cmax) were reduced by an average of 79% and 71%, respectively, when administered to healthy volunteers (n=40) treated with the strong CYP3A inducer rifampin (600 mg/day x 9 days).<sup>1</sup> Considering these findings the axitinib prescribing information recommends avoiding concurrent use with any strong or moderate inducer of CYP3A.<sup>2</sup><br><br>The likely mechanism for this interaction is induction of the CYP3A-mediated metabolism of axitinib, whose metabolism is primarily via CYP3A.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pithavala YK, Tortorici M, Toh M, et al. Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. <i>Cancer Chemother Pharmacol</i>. 2010;65(3):563-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19603168\">[PubMed 19603168]</a></p>\n<p>2. <i>Inlyta</i> (axitinib) [prescribing information]. New York, NY: Pfizer Inc; January 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","8898":"<p><b>Title</b> Bosutinib / CYP3A4 Inducers (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of bosutinib with any moderate CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Moderate) Interacting Members</b> Bexarotene (Systemic), Bosentan, Dabrafenib, Efavirenz, Eslicarbazepine, Etravirine, Modafinil, Nafcillin, Rifapentine, St John's Wort</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 24 healthy volunteers, coadministration of rifampin (600 mg orally daily for 6 days) decreased bosutinib (500 mg single oral dose) maximum concentration and AUC by 86% and 94%, respectively.<sup>1</sup> <br><br>The suspected primary mechanism of this interaction is rifampin induction of the CYP3A4 mediated metabolism and/or P-glycoprotein mediated efflux of bosutinib. Bosutinib prescribing information specifically states that coadministration with strong or moderate CYP3A4 inducers should be avoided.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Bosulif</i> (bosutinib) [prescribing information]. New York, NY: Pfizer Inc; September 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}